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Abstract 
 
Major depressive disorder (MDD), the most prevalent mental illness, is a chronic 
and recurrent condition (Lucas et al., 2011). MDD seems to be associated with 
abnormalities in regions that mediate emotional and stress responses (Manji et al., 
2001). A strong link between suicide and depression has been showed, with more than 
86% of suicide victims having a depressive disorder, and committing suicide most often 
after a major depressive episode (Coryell & Young, 2005; Rihmer, 2007). So, it is 
possible to study the brain tissue from suicide completers, in order to understand the 
neurobiological basis of depression. Suicide has been identified as a serious public 
health problem. Risk factors, such as biological, psychiatric and cultural, interact in a 
complex manner to this pathology (Bertolote & Fleischmann, 2005).  
Adenosine is an endogenous nucleoside that influences many functions in the 
central nervous system (CNS) (Fredholm et al., 2005), acting as a homeostatic 
modulator and also as a neuromodulator at the synaptic level, where it modulates the 
release of neurotransmitters, the post-synaptic responsiveness and the action of other 
receptor systems (Cunha, 2001). Adenosine acts via activation of four G-protein 
coupled receptors (GPCRs) (Fredholm, 1997), in the brain, it acts especially through 
activation of two adenosine receptors (ARs), inhibitory A1 (A1R) and facilitatory A2A 
(A2AR) receptors (Cunha, 2005; Wei et al., 2011). 
The interest in the role of adenosine in mood disorders arised from previous studies 
that have recognized a relationship between caffeine intake, mood changes and 
specific psychiatric symptoms (Kawachi et al., 1996; Lara, 2010; Lucas et al., 2011; 
Lucas et al., 2013), since caffeine has biological effects as competitive antagonist of 
A1R and A2AR (Chen et al., 2013; Cunha et al., 2008; El Yacoubi et al., 2003; Fredholm 
et al., 2005; Fredholm, 2007). There is also evidence that different therapeutic 
strategies used to control mood disorders are related to the adenosine modulation 
system (Chen et al., 2013; Cunha et al., 2008; El Yacoubi et al., 2001; Gomes et al., 
2011). In animal models of manipulation of ARs, there are modified behavioral 
responses considered relevant for mood in humans (Gomes et al., 2011). 
The main goal of this study was to understand the differences in the localization, 
density and function of both A1R and A2AR between control subjects and suicide 
completers, in brain areas affected by depression. Also, we aimed to comprehend if 
these alterations are related with synaptic changes. For this purpose, a postmortem 
study was performed in male subjects who died by suicide, aged-matched with non-
suicide controls who died by natural causes or accidents. Human brain samples were 
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obtained at autopsies performed in Instituto Nacional de Medicina Legal e Ciências 
Forenses, I. P. (INMLCF), Coimbra, Portugal. Several brain areas were studied: 
Brodmann area 25 (BA25); medial caudate nucleus (MC); posterior caudate nucleus 
(PC) and hippocampus. 
To comprehend the normal localization of A1R and A2AR we compared the 
relative abundance of A1R and A2AR in total extracts (TE) and in nerve terminals (NT), 
isolated using an adapted discontinuous Percoll gradient protocol (Dunkley et al., 1986, 
2008), from human brain areas of the same sample. In all brain areas studied, both 
receptors were found enriched in NT. We then refined the information on ARs 
subsynaptic localization, using a fractionation method (Phillips et al., 2001; Rebola et 
al., 2005), and it was observed that A2AR are mainly located outside the active zone 
and A1R are present in all synaptic fractions. 
Synaptic changes present in the brain of suicide completers were then studied 
and it was observed a down-regulation of synaptosomal-associated protein 25 (SNAP-
25) on BA25 and MC together with a decrease in postsynaptic density protein 95 (PSD-
95) levels on PC and hippocampus. Astrocytic marker glial fibrillary acidic protein 
(GFAP) down-regulation was observed in BA25 and hippocampus. 
Several alterations in the density of ARs, in the different brain regions, were 
observed in suicide completers when compared with age-matched controls. We 
described: an up-regulation of A2AR in TE, on BA25 and PC; an up-regulation of A1R in 
TE, on MC; a down-regulation of A1R in NT, on PC. 
Due to their particular distribution in the brain and their functional properties, ARs 
constitute an attractive opportunity for developing innovative compounds for the 
treatment of specific neurodegenerative and psychiatric disorders, such as MDD. Our 
work has provided information about changes present in the brains of suicide 
completers and might contribute to better understand the modulatory role of ARs in 
depression. There are still numerous questions that demand careful attention to further 
explore this system and develop novel strategies to control mood disorders, particularly 
MDD.  
 
Keywords: Postmortem human brain; Suicide; Major depressive disorder; Adenosine 
A1 receptor; Adenosine A2A receptor. 
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Resumo 
 
A perturbação depressiva major (MDD), a mais predominante das doenças 
mentais, é uma condição crónica e recorrente (Lucas et al., 2011). A MDD parece 
estar associada com alterações nas regiões que medeiam as respostas emocionais e 
de stress (Manji et al., 2001). Uma forte ligação entre o suicídio e a depressão foi 
demonstrada, uma vez que mais de 86% das vítimas de suicídio apresentavam uma 
perturbação depressiva, na maioria dos casos, ocorrendo o suicídio depois de um 
episódio depressivo major (Coryell et al., 2005; Rihmer, 2007). Assim, o tecido cerebral 
de vítimas de suicídio pode ser utilizado para estudar a neurobiologia da depressão. O 
suicídio foi identificado como um problema sério de saúde pública. Vários fatores de 
risco biológicos, psiquiátricos e culturais interagem de uma maneira complexa para 
esta patologia (Bertolote & Fleischmann, 2005).  
A adenosina é um nucleósido endógeno que influencia muitas funções do sistema 
nervoso central (CNS), agindo como modulador homeostático e também como 
neuromodulador ao nível sináptico, onde modula a libertação de neurotransmissores, a 
capacidade de resposta pós-sináptica e a ação de outros sistemas receptores (CNS) 
(Cunha, 2001; Fredholm et al., 2005). A adenosina actua em quatro receptores 
acoplados à proteína G (GPCRs) (Fredholm, 2007), no cérebro age especialmente 
através da activação de dois receptores de adenosina (ARs), inibitório A1 (A1R) e 
facilitatório A2A (A2AR) receptores (Cunha, 2005; Wei et al., 2011). 
O interesse do papel da adenosina nos distúrbios de humor surgiu de numerosos 
estudos que reconheceram uma relação entre o consumo de cafeína, alterações de 
humor e sintomas psiquiátricos específicos (Kawachi et al., 1996; Lara, 2010; Lucas et 
al., 2011; Lucas et al., 2013), uma vez que a cafeína tem efeitos biológicos como 
antagonista competitivo dos A1R e A2AR (Chen et al., 2013; Cunha et al., 2008; El 
Yacoubi et al., 2003; Fredholm et al., 2005; Fredholm, 2007). Também há evidências 
de que as estratégias terapêuticas utilizadas para controlar distúrbios de humor estão 
relacionados com o sistema modulatório de adenosina (Chen et al., 2013; Cunha et al., 
2008; El Yacoubi et al., 2001; Gomes et al., 2011). Em modelos animais de 
manipulação de ARs há respostas comportamentais consideradas relevantes para o 
humor nos humanos (Gomes et al., 2011). 
O principal objectivo deste estudo era perceber as diferenças na localização, 
densidade e função dos A1R e A2AR, entre vítimas de suicídio e controlos, em áreas 
afectadas pela depressão. Além disso, tentámos compreender se essas alterações 
estão relacionadas com modificações sinápticas. Para este propósito foi realizado um 
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estudo postmortem em sujeitos do sexo masculino suicidas, pareados com controlos 
da mesma idade que morreram de causas naturais ou acidentes. As amostras de 
cérebro humano foram obtidas em autópsias realizadas no Instituto Nacional de 
Medicina Legal e Ciências Forenses, I. P. (INMLCF), Coimbra, Portugal. Foram 
estudadas diversas áreas cerebrais: área de Brodmann 25 (BA25); núcleo caudado 
médio (MC); núcleo caudado posterior (PC) e hipocampo.  
Para compreender a localização normal dos A1R e do A2AR comparámos a 
abundância relativa dos ARs em extratos totais (TE) e em terminais nervosos (NT), 
isolados usando um protocolo adaptado de gradiente de Percoll discontínuo (Dunkley 
et al., 1986, 2008), das áreas cerebrais da mesma amostra. Em todas as áreas 
estudadas os dois receptores encontram-se enriquecidos nos NT. De seguida, 
refinámos a informação acerca da localização subsináptica dos ARs, usando um 
método de fracciomento (Phillips et al., 2001; Rebola et al., 2005) e foi observado que 
os A2AR estão maioritariamente localizados fora da zona activa da sinapse e os A1R 
estão presentes em todas as fracções sinápticas. 
Foram então estudadas alterações sinápticas presentes no cérebro de suicidas 
e foi observada uma diminuição de densidade da synaptosomal-associated protein 25 
(SNAP-25) na BA25 e no MC juntamente com um decréscimo nos níveis de 
postsynaptic density protein 95 (PSD-95) no PC e no hipocampo. Foi observado uma 
diminuição da densidade do marcador astrocítico glial fibrillary acidic protein (GFAP) 
na BA25 e no hipocampo. 
Várias alterações na densidade dos ARs, nas diferentes regiões do cérebro, 
foram observadas nas amostras de suicidas quando comparadas com os controlos. 
Nós descrevemos: aumento da densidade de A2AR em TE, na BA25 e no PC; aumento 
de densidade de A1R em TE, no MC; diminuição de densidade de A1R em NT, no PC.  
Devido à sua particular distribuição no cérebro e as suas propriedades 
funcionais, os ARs constituem uma oportunidade atrativa para desenvolver compostos 
inovadores para o tratamento de distúrbios psiquiátricos e neurodegenerativos, como a 
MDD. O nosso trabalho forneceu informação sobre as mudanças presentes no cérebro 
de suicidas e pode contribuir para uma melhor compreensão do papel modulador dos 
ARs na depressão. Há ainda numerosas questões, que requerem atenção cuidadosa, 
para continuar a explorar este sistema e desenvolver novas estratégias para controlar 
os distúrbios de humor, particularmente, a MDD. 
 
Palavras-chave: Cérebro humano postmortem; Suicídio; Perturbação depressiva 
major; Receptor de adenosina A1; Receptor de adenosina A2A. 
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1.1 Major depressive disorder 
 
Major depressive disorder (MDD), the most prevalent mental illness, 
dramatically impairs the quality of life and represents a life-threatening condition 
(Manji et al., 2001; Nemeroff & Owens, 2002; World Health Organization, 2011). It 
affects up to 20% of the global population (Berton & Nestler, 2006; Krishnan & 
Nestler, 2008; Nestler et al., 2002), and by 2020, MDD will be the second leading 
cause of global disability burden (Murray & Lopez, 1997). 
Psychiatric disorders are defined through recognized classifications such as 
the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) on the 
basis of behavioral modifications found in patients in comparison with a standardized 
population. Although ongoing studies, the neurobiological basis of depression is, so 
far, not well understood (Krishnan & Nestler, 2008). 
MDD is a chronic and recurrent condition (Lucas et al., 2011), characterized by 
one or more major depressive episodes, without history of maniac, mist or 
hippomaniac episodes (American Psychiatric Association, 2013). A major depressive 
episode is characterized by a period of at least two weeks during which the individual 
presents a depressive mood or a loss of interest in almost all activities, together with 
at least four additional symptoms of depression (American Psychiatric Association, 
2013). Depressive mood can be described by: sadness, loss of interest or pleasure, 
feelings of guilt or low self-esteem, disturbed sleep or appetite, feelings of exhaustion, 
and reduced concentration, that can impair the ability to function at work and handle 
daily life (American Psychiatric Association, 2013). Disease phenotypes of MDD 
include not only episodic and persistent mood disturbances, but also a series of 
cognitive, motoric, autonomic, endocrine and sleep/wake abnormalities (Manji et al., 
2001). Approximately 15% of individuals with MDD can die by suicide (American 
Psychiatric Association 2013), and many other deleterious health-related effects have 
been documented. MDD, apart from being a disease with psychological 
manifestations, is a systemic disease with deleterious effects on multiple organ 
systems (Manji et al., 2001). 
 
Regardless of its prevalence and substantial impact, there is still a lot to know 
about its pathogenesis. One major difficulty in studying MDD is to develop an animal 
model that truly mimics the patient symptoms, as some of this disorder hallmarks, such 
as depressed mood, low self-esteem or suicidality, are hardly accessible in non-
humans (Yan et al., 2010). 
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As MDD can be hastened by stressful life events, the majority of animal 
models of depression are based on induced stress (Yan et al., 2010). These include 
several models, such as, the learned helplessness (Chourbaji et al., 2005), the 
chronic mild stress (Willner, 2005) and the social defeat stress (Golden et al., 2011). 
Models of early life stress are also used, producing significant effects that last until 
adulthood (Ladd et al., 2000). Despite the above mentioned models, other types are 
used, such as pharmacological, lesion and mutant models (Yan et al., 2010).  
 
As previously stated, the major obstacle of research on MDD pathogenesis is 
the fact that the currently available validated animal models represent only some of 
the MDD features, but not the pathogenesis (Yan et al., 2010). However, almost all 
mental disorders can increase the risk for suicide (Bertolote & Fleischmann 2002), 
research has shown a strong link between suicide and depression, with, at least, 86% 
of the suicide victims having a depressive disorder, most often accomplished during or 
after a major depressive episode (Coryell & Young, 2005; Rihmer, 2007). So, the brain 
tissue from suicide completers can be studied in order to understand the 
neurobiological basis of depression. 
Suicide is a serious public health problem, being among the 10 leading causes 
of death for most countries at all ages (Bertolote & Fleischmann, 2005). Around the 
world, in the year 2002, approximately 877,000 people committed suicide, which 
represents a global mortality rate of 16 per 100,000 or one death every 40 seconds 
(Bertolote & Fleischmann, 2005). This rate varies regarding different demographic 
groups and geographic regions. Furthermore, by 2020, it is estimated that 
approximately 1.53 million people will die from suicide (Bertolote & Fleischmann, 
2005). In Portugal, suicide is the major cause of non-natural death (Freitas, 2010).  
 
Positron emission tomography (PET) imaging studies, that evaluate cerebral 
blood flow (CBF) and glucose metabolism, showed multiple abnormalities in mood 
disorder patients, relative to healthy patients (Mayberg, 2003). Abnormalities of several 
brain structures were also demonstrated by magnetic resonance imaging (MRI) and 
postmortem investigations (Manji et al., 2001). Findings, albeit not homogeneous, 
denote reductions in hippocampus volume (Bremner et al., 2000; Caetano et al., 2004; 
Frodl et al., 2006; Neumeister et al., 2005; Sheline et al., 2003) with greater impact on 
more persistent forms of MDD (Lorenzetti et al., 2009). Evidences further support 
volumetric alterations in the basal ganglia (Bonelli et al., 2006; Hickie et al., 2007; Pillay 
et al., 1998), and it seems that the caudate nucleus, putamen and globus pallidus may 
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be impaired in more severe subtypes of depression (Lorenzetti et al., 2009). Alterations 
in the anterior cingulate cortex (ACC), particularly a sub-region usually termed 
Brodmann area 25 (BA25), have been observed in functional neuroimaging studies of 
depressed patients (Gotlib et al., 2005; Pizzagalli et al., 2004).  
These evidences indicated a dysregulation of limbic and cortical regions 
involved in emotional regulation and experience (Davidson et al., 2002; Mayberg, 1997; 
Phillips et al., 2003a, b), including hippocampus, amygdala, ACC, orbital frontal cortex 
(OFC) and basal ganglia (Lorenzetti et al., 2009). 
 
 
Figure 1. Regions, neurotransmitters and circuits implicated in the pathology of major 
depressive disorder (MDD) by human neuroimaging studies (adapted from Treadway & 
Pizzagalli, 2014). 
 
BA25 is a “node” in a network connecting the cortex with limbic regions and 
brainstem (Pandya et al., 1981). 
The striatum, comprising the caudate nucleus and putamen, is the primary input 
structure to the basal ganglia circuitry, serving as an emotional-motor interface. 
Through the selective distribution of the axonal terminal arborizations of cortical 
sources it is relatively segregated to differentially support motor, executive, and 
affective or limbic processing (Furman et al., 2011). Basal ganglia receives projections 
from the frontal cortex, comprising ACC and OFC, as well as by associative cortex and 
limbic regions, comprehending the hippocampus, amygdala and related regions. 
Output neurons project from the basal ganglia to the midbrain and thalamus, which 
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return to the frontal cortex, so that the information is processed and then relayed back 
to distinct cortical regions (Furman et al., 2011).  
The striatum and globus pallidus are organized in parallel to connect with 
cortical and limbic regions (Furman et al., 2011). Afferent and efferent neurons of the 
hippocampus are bundled together in the same paths. The two major pathways are the 
fornix and entorhinal cortex, via the cingulate cortex (Sheline, 2003). The fornix 
connects to the septum, striatum and hypothalamus. In turn, the cingulate cortex, 
projects to the temporal lobe cortex, orbital cortex, and olfactory bulb (Sheline, 2003). 
Anomalous connectivity of the frontostriatal linkages contributes to the 
anhedonic, ruminative and psychomotor dysfunctions characteristics of MDD (Furman 
et al., 2011). Neocortex and hippocampus may mediate cognitive aspects of 
depression besides memory impairments, such as feelings of worthlessness, 
hopelessness, guilt, doom, and suicidality (Krishnan & Nestler, 2008). The striatum, 
amygdala and related brain areas, are important in emotional memory, and can 
mediate: increased anxiety; decreased initiative, reward for pleasant activities and 
motivation (Krishnan & Nestler, 2008). Lack or excess of sleep, appetite, and energy, 
as well as a loss of interest in sex and other pleasurable activities, implicates a role for 
the hypothalamus (Nestler et al., 2002). The frontal cortex, besides being relevant for 
cognitive functions, is also important for modulation of basal ganglia and limbic regions 
activity (Sheline, 2003). 
Many patients with MDD seem to display disruption of brain networks (Menon, 
2011) and characteristics of a neuroprogressive illness (Moylan et al., 2013). 
Numerous neurobiological pathways can interact simultaneously, contributing to this 
pathogenesis, including neurotransmitter systems with disruption of monoaminergic 
transmission, such as serotonergic, dopaminergic and noradrenergic (Moylan et al., 
2013). Evidences for other neurotransmission system disruption also exist, such as 
cholinergic, GABAergic and glutamatergic (Manji, 2001). 
MDD may also be related to abnormalities in the circadian rhythm (Carlson, 
2013) and the hypothalamic-pituitary-adrenal (HPA) axis, activated during the body's 
response to stressors, seems to be overactive in depressed patients (Pariante & 
Lightman, 2008). 
As so, biological theories of depression must comprehend systems necessary 
for the processing and experience of emotions, involving autonomic, endocrine and 
cognitive states that couple the perception of stimuli to an adaptive behavioral 
response (Mayberg, 2000). 
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Table 1. Comparison of human postmortem studies in depression (adapted from Russo 
& Nestler, 2013). 
Brain region Human postmortem analysis 
Hippocampus 
↓ Synapses density 
↓ Glial cell density 
Basolateral amygdala 
↓ Grey matter 
↓ Glial cell density 
Medial prefrontal cortex 
↓ White matter 
↓ Dendritic branching 
↓ Glial cell density 
 
At cellular level, depression can be characterized by a decreased neuronal 
soma size in cortical and hippocampal neurons and increased packing density in 
hippocampal neurons (Stockmeier & Rajkowska, 2004). Results from previous studies 
also indicate the presence of a synaptic pathology in the ACC in mood disorders, 
contributing to the dysfunction of cingulate neural circuits (Eastwodd & Harrison, 
2001). Earlier findings suggest abnormalties of SNARE (SNAP receptor) mechanism 
proteins, a fundamental molecular component of neural connectivity which consists of 
three proteins, syntaxin, synaptosomal-associated protein 25 (SNAP-25) and vesicle-
associated membrane protein (VAMP) in mental disorders (Hones et al., 2002). 
Abnormalities in glutamatergic transmission in MDD have been reported, and the 
results revealed a reduction in PSD-95 expression levels (Feyissaa et al., 2009). 
Additionally, MDD is linked to deregulation of neurotransmission, decreased neuronal 
synapses and failure in synaptic plasticity in areas that regulate mood. The alterations 
seem to particularly affect excitatory connections and may be progressive (Eastwodd 
& Harrison, 2001; Femenia et al., 2012). MDD is also characterized by alterations in 
size and shape of glial cells, indicative of reduction in the number of normally 
functioning glial cells (Stockmeier & Rajkowska, 2004). Changes in astrocytes density 
and in the expression of their markers have been shown (Stockmeier & Rajkowska, 
2004), along with microglial activation (Steiner et al., 2011). Impairments in glia can 
lead to deficiency in neurotrophic and angiogenic factors and disturbed myelination 
that are likely to contribute to the pathophysiology of MDD (Rajkowska et al., 2007). 
As glia, especially astrocytes, regulates the levels of extracellular glutamate, and thus 
protects neurons from cell death and provides them energy, astrocytic pathology may 
also promote glutamate-mediated neuronal excitotoxicity (Stockmeier & Rajkowska, 
2004).  
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There are several treatments available that vary according to the severity of 
the disease. Current available therapeutics are antidepressants, certain forms of 
psychotherapy and electroconvulsive therapy (ECT) (Gomes et al., 2011; Nemeroff & 
Owens, 2002). All approved classes of antidepressants act in blockade of presynaptic 
monoamine transporter proteins, inhibition of monoamine oxidase, or inhibition or 
excitation of pre- or postsynaptic receptors (Gomes et al., 2011; Nemeroff & Owens, 
2002). ECT antipsychotic effects are associated with normalization of BA25 theta 
hypoactivity (McCormick et al., 2009). These treatments are safe, however, less than 
half of patients achieve complete remission, and others exhibit partial or intolerant 
responses to treatment (Gomes et al., 2011). This highlights the inadequacy of 
currently available treatments and the need to discover new antidepressants (Gomes 
et al., 2011; Nemeroff & Owens, 2002). New treatment techniques, such as deep 
brain stimulation (DBS) (Malone et al,. 2009; Mayberg et al., 2005; Holtzheimer & 
Mayberg, 2010) and transcranial magnetic stimulation (TMS) (Carpenter et al., 2012; 
Janicak et al., 2013) are emerging, based on the differential neural responses in 
cortico-striato-limbic circuits of depressed patients (Treadway & Pizzagalli, 2014). 
Ongoing research aims to define the cause for depression, finding new 
biomarkers, developing diagnostic tests and better treatments based on these brain 
alterations. 
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1.2 Adenosine 
 
1.2.1 An endogenous neuromodulator 
Physiological actions of adenosine exogenously administered were first 
described by Drury and Szent-Györgyi in 1929, who observed pronounced 
cardiovascular effects. The discovery made by Sattin and Rail in 1970 that, in brain 
cells, adenosine stimulates cyclic adenosine monophosphate (cAMP) formation, began 
a new stage of adenosine research, leading to the discovery of adenosine receptors 
(ARs) and their subclassification (Mueller & Scior, 1993). 
Adenosine does not act as a neurotransmitter, once it is not stored in vesicles or 
released by exocytosis, it does not transfer information unidirectionally from 
presynaptic to postsynaptic components, or act only or predominantly in synapses 
(Fredholm et al., 2005). Instead, the nucleoside adenosine exerts two modulatory 
influences in the Central Nervous System (CNS), acting as a homeostatic modulator 
and also as a neuromodulator at the synaptic level. As a neuromodulator: it controls the 
flow of information between neurons in the brain by fine tuning on-going synaptic 
transmission; as an upstream regulator of a wide-range of neurotransmitters, it also 
modulates post-synaptic responsiveness action of other receptor systems and signaling 
pathways that converge to contribute to the expression of an array of important brain 
functions (Cunha, 2001; Cunha, 2005; Cunha, 2008; Fredholm et al., 2005; Prediger et 
al., 2006; Svenningsson et al., 1999; Wei et al., 2011). 
The concentration of adenosine in the extracellular compartment is the 
consequence of many biological processes, being formed inside or outside cells, it can 
appear in the extracellular milieu through different mechanisms (Chen et al., 2013; 
Fredholm et al., 2005; Fredholm, 2007). Adenosine can be released through 
nucleoside transporters, after an increase in the intracellular levels of adenosine or a 
reversal of the sodium gradient; can be formed in the extracellular space through the 
ectonucleotidase pathway on release of adenine nucleotides, especially adenosine 
triphosphate (ATP); or after release of cAMP, but this pathway has been found to be of 
minor importance when physiological parameters affected by adenosine are being 
studied (Cunha, 2008; Fredholm et al., 2005; Fredholm, 2007). 
Extracellular adenosine, which is relevant for modulation of synaptic 
transmission, might originate not only from nerve terminals but also from the activated 
postsynaptic component and from surrounding non neuronal cells, depending on the 
stimuli (Cunha 2008; Fredholm et al. 2005; Fredholm 2007).  
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Nonconcentrative nucleoside transporters and enzymes of adenosine 
metabolism regulate extracellular concentrations of adenosine. Adenosine deaminase 
(ADA) and adenosine kinase (ADK) generally reduce adenosine concentrations by 
forming inosine and AMP, respectively. ADK is the primary route of adenosine 
metabolism with ADA coming into play only when large amounts of adenosine have to 
be cleared (Fredholm et al., 2005). During brain development there is a change in the 
location of ADK, with a transition from a predominantly neuronal expression to a 
predominantly astrocytic expression (Boison, 2006). ADA is more abundant in 
astrocytes, than in neurons, reflecting the importance of non neuronal uptake of 
adenosine (Fredholm et al., 2005). 
The activity of nucleoside transporters can be regulated by the activation of ARs 
through protein kinase pathways (Fredholm et al., 2005). 
 
1.2.2 Adenosine receptors 
Adenosine is a purine nucleoside that exists in all cells, where it is a metabolite 
involved in key pathways of primary metabolism and a constituent of other bioactive 
molecules. The intra- and extracellular levels of adenosine equilibrate with each one, 
so, if the levels of intracellular adenosine rise in a particular cell, the extracellular 
adenosine levels will gradually increase in the surroundings of the cell. Extracellular 
adenosine is then capable to act on ARs located both in the cell membrane of 
neighbouring cells and in the cell that released adenosine in the first place (Cunha, 
2005). 
ARs are a family of cell surface receptors and so far there are four subtypes 
known and pharmacologically characterized: A1, A2A, A2B, and A3. The ARs are G 
protein-coupled receptors (GPCRs) and consist of a single polypeptide chain that 
transverses the membrane from the extracellular side beginning at the N terminus to 
form seven transmembrane helices. The A1 and A3 receptors preferentially couple to Gi 
protein, and the A2A and A2B receptors subtypes couple to Gs or Go (Chen et al., 2013; 
Cunha, 2005; Fredholm, 2007; Moreau & Huber, 1999; Mueller et al., 2011; Prediger et 
al., 2006; Sciotti et al., 1992), but it seems that all ARs have potential to couple to 
different G proteins and to different transducing systems, depending on their degree of 
activation and their particular cellular and sub-cellular localization (Cunha, 2005).  
A2B and A3 receptors have low abundance in the brain, thus, the role of 
adenosine in the brain, to modulate neurotransmitter systems, neuronal excitability, and 
synaptic plasticity, is currently considered to be mediated by a balanced activation of A1 
and A2A receptors (Cunha, 2005; Wei et al., 2011). This balanced activation depends 
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not only on the transient levels of extracellular adenosine, but also on the direct 
interaction between both receptors. So, at low concentrations of extracellular 
adenosine, A1 receptor-mediated tonic inhibition of neurotransmitter release 
predominates and, as the concentration of adenosine rises, A2A receptor modulation 
prevails (Cunha, 2001; Cunha, 2005).  
The different ARs subtypes differ with regard to control of their expression and 
their rate of desensitization/resensitization, and upon prolonged exposure to agonists 
all ARs subtypes desensitize (Fredholm et al., 2005). The ARs have also been 
proposed to participate in both homo and heterodimerization or even oligomerization 
(Mueller et al., 2011; Uriguen et al., 2009). 
Even though ARs are widespread in the brain, they are not homogeneously 
located in brain regions or cell types (Cunha, 2005; Cunha, 2008; Fredholm et al., 
2005; Svenningsson et al., 1999; Uriguen et al., 2009; Wei et al., 2011).  
 
1.2.2.1 A1 receptor 
The A1 receptor is the most highly conserved ARs subtype between species and 
probably exhibits the greatest affinity for adenosine (Chen et al., 2013; Cunha, 2005; 
Cunha, 2008; Fredholm et al., 2005; Wei et al., 2011). 
Its activation inhibits adenylate cyclase (AC) activity, activates potassium 
channels (including KATP channels), blocks transient calcium channels and increases 
inositol-1,4,5-trisphosphate and intracellular calcium levels by activating phospholipase 
C (PLC), it modulates neuronal activity by blocking neurotransmitter release and 
reducing the firing rate (Chen et al., 2013). 
It is widely expressed throughout the body with the highest levels found in the 
brain, especially at excitatory nerve endings (Chen et al., 2013; Cunha, 2005; Cunha, 
2008; Fredholm et al., 2005; Wei et al., 2011) in neurons of cortex, hippocampus, and 
cerebellum and only moderately expressed in striatum, being also expressed at 
intermediate levels elsewhere in the brain (Chen et al., 2013; Wei et al., 2011).  
From previous studies in rodents, we know that although especially found in 
neurons, they are also located in other cell types in the brain, such as astrocytes, 
microglia, and oligodendrocytes (Fredholm et al., 2005). At sub-cellular level, A1 
receptors were mostly found in nerve terminals in the plasma membrane, at both pre-
synaptic zone and postsynaptic density, in hippocampus (Rebola et al., 2003).  
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1.2.2.2 A2A receptor 
A2A receptor also exhibits a high affinity for adenosine and is widely expressed 
in different tissues, at varying levels (Cunha, 2005; Fredholm et al., 2005; Moreau & 
Huber, 1999; Schiffmann et al., 1991; Svenningsson et al., 1999). 
In the brain, A2A receptor activation stimulates the protein kinase A (PKA) 
pathway (Chen et al., 2013; Fredholm et al. 2005; Wei et al., 2011) and may also signal 
through a protein kinase C (PKC) pathway or even trigger alternative signaling 
pathways, by interacting with other receptors and signaling molecules (Wei et al., 
2011), regulating motor activity, psychiatric behaviors, the sleep/wake cycle and 
neuronal cell death (Chen et al., 2013). In a G protein-independent way, A2A receptors 
might mediate other signaling pathways responsible for regulation of its own expression 
and the activation of mitogen-activated protein kinase (MAPK) (Fredholm, 2007). 
Within brain, A2A receptors are concentrated in basal ganglia, predominantly 
expressed in striatum, but they are also present throughout the brain with a 
considerably lower density (Cunha, 2005; Fredholm et al., 2005). In extrastriatal areas, 
distinct levels are found in the cortex, amygdala, olfactory tubercles, hippocampus, 
hypothalamus, thalamus and cerebellum (Cunha, 2005; Fredholm et al., 2005; Moreau 
& Huber, 1999; Schiffmann et al., 1991; Svenningsson et al., 1999). 
In previous studies, using rodent samples, A2A receptors were present in 
neurons and also in astrocytes, microglia, and blood vessels throughout the brain 
(Fredholm et al., 2005). At sub-cellular level, A2A receptors were found in the active 
zone of the pre-synaptic sites nerve terminals of hippocampus, whereas in the striatum 
is predominantly located at post-synaptic density, while a minority is located in the pre-
synaptic site in cortico-striatal terminals (Fredholm et al., 2005; Rebola et al., 2005; Wei 
et al., 2011). 
Although in rodents and humans the distribution of A2A receptors is similar, the 
extrastriatal levels appear to be higher in humans than in rodents (Fredholm et al., 
2005).  
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1.3 Mood and adenosine 
 
Adenosine and its analogues have been shown to produce depressant-like 
behavioral effects, relevant for human condition (Minor et al., 1994; Woodson et al., 
1998). 
Patients with MDD, in clinical studies, were found to have reduced serum ADA 
activity, with a consequent increase in adenosine tonus, which was inversely 
correlated with disease severity (Wei et al., 2011). 
Furthermore, animal models designed to reveal the neurobiological basis of 
depression point to a role for ARs, in the regulation of mood (Batalha et al., 2013; 
Gomes et al., 2011; Wei et al., 2011). 
The strongest evidence supporting the relation between adenosine and 
depression in preclinical models came from manipulation of ARs, both selective A2A 
receptor receptor blockade by antagonists, as well as global A2A receptor genetic 
depletion were shown to reverse signs of behavioral despair in the tail suspension and 
forced swim tests, independently of its hyperlocomotor effect (El Yacoubi et al., 2001; 
El Yacoubi et al., 2003; Moreau & Huber, 1999; Wei et al., 2011). In animal models, it is 
possible to implicate endogenous adenosine neuroregulation as a central 
compensatory mechanism in learned helplessness and conservation-withdrawal (Minor 
et al., 1994; Woodson et al., 1998). 
Stress is a known risk factor for depression, so, the study of animal models of 
chronic stress can help to discover potential anti-depressant drugs. A2A receptors seem 
to be involved in the stress-associated impairments, as the administration of a selective 
antagonist reverts the consequences of stress on spatial memory, synaptic plasticity 
and neuronal morphology in the hippocampus (Batalha et al., 2013).  
Several epidemiological studies have explored a relationship between caffeine 
intake, mood changes and specific psychiatric symptoms (Cunha et al., 2008; Gomes 
et al., 2011). These studies are important to understand the role of the adenosine 
modulation system in the control of mood, since methylxanthines, such as caffeine 
(1,3,7-trimethylxanthine), have profound biological effects as competitive antagonists 
of A1 and A2A receptors (Chen et al., 2013; El Yacoubi et al., 2003; Fredholm, 2007), 
and they are the only known molecular target of caffeine, at nontoxic doses (Cunha et 
al., 2008; Fredholm et al., 2005). Coffee consumption may bring benefits related to its 
psychostimulant effects, increasing alertness (Lara, 2010; Smith, 2002). Additionally 
coffee consumption is considered to improve psychomotor performance, cognition 
and elevate mood in humans (Cunha et al., 2008; El Yacoubi et al., 2003; Lara, 2010). 
Role of adenosine receptors in suicide 
13 
 
Furthermore, moderate coffee intake has been associated with reduced risk of 
depression in a dose-dependent manner (Lucas et al., 2011; Lucas et al., 2013). Prior 
observations also suggest that suicide risk is lower among persons with higher 
consumption of coffee (Kawachi et al., 1996). Even though it has psychostimulant 
effects at low to moderate doses, they are dose dependent and typically biphasic, so, 
with higher doses, the reverse effect can be observed (Lucas et al., 2011), triggering 
behavioral modifications, both anxiety disorders as well as depressive-like conditions. 
Similar effects to high doses of caffeine are reported during withdrawal (Juliano & 
Griffiths, 2004; Kruger, 1996; Stephenson, 1977). The threshold for the anxiogenic 
effect of caffeine seems to be influenced by a polymorphism of the A2A receptor, being 
restricted to some individuals with at least a predisposition for specific anxiety 
disorders, and is influenced by genetic and ethnic factors (Lara, 2010).  
Studies trying to explain the mechanisms underlying antidepressant action 
have shown effects related to the adenosine system (Gomes et al., 2011), as many 
drugs clinically used to manage depressive disorders may exert their effects by 
altering extracellular adenosine concentrations and signaling (Chen et al., 2013), 
binding to ARs and, in a dose-dependent manner, reducing the activity of 
ectonucleotidases. Also, antidepressants reverse the adenosine-induced immobility in 
animals submitted to inescapable shocks and forced swimming tests (Kulkarni & 
Mehta, 1985). 
Additionally, strategies used to control mood disorders, as ECT and sleep 
deprivation (SD), cause an adaptation of the adenosine neuromodulator system, 
increasing adenosine concentration and A1 receptor activation (Gomes et al., 2011). 
For instance, antidepressive-like benefits of SD require astrocytic signaling through A1 
synaptic receptors (Hines et al., 2013). Short-term adaptive neuronal response is 
triggered through inhibitory A1 receptors, in slow wave sleep and cerebral metabolic 
activity; and long term adaptive changes through up-regulation of A1 and probably of 
A2A receptors (Gomes et al., 2011). 
Adenosine neuromodulation system actions in depression are complex, due to 
its ability to modulate several neurotransmission systems (dopaminergic, 
glutamatergic and serotonergic as well as the corticotrophin system) (Gomes et al., 
2011); glial metabolism and neuroinflammation (Cunha et al., 2008; Uriguen et al., 
2009). And so far, it is unknown whether the manipulation of both A1 and A2A 
receptors, a neuroprotective strategy suggested for other disorders and pathologies, 
can be explored for MDD. 
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To sum up, since the discovery of its physiological actions, adenosine system 
is a target for drug development (Gomes et al., 2011). 
The main function of adenosine neuromodulation system is to maintain 
homeostasis and promote adaptation of neuronal systems, acting as a normalizing 
system by limiting edges of extreme functioning of biological systems, modulating 
anxiety, exploration, aggressive behaviors, depressive responses, and sensorimotor 
gating (Lopes et al., 2011). Therefore, excess or reduced adenosine in a system, and 
subsequently too high or too low ARs activation or expression levels, will lead to a 
failure in adapting to environment and cause a predisposition to disease (Gomes et 
al., 2011). 
ARs distribution in the brain and their functional properties create an 
opportunity to develop new compounds for the treatment of neurodegenerative and 
psychiatric disorders, such as MDD. The adenosine system can be used to 
manipulate brain circuits to restore their proper function, and there seems to be a 
parallel benefit of manipulating both A1 and A2A receptors (Cunha, 2005).  
There are still numerous questions that demand careful attention to further 
explore this system and develop novel strategies to control mood disorders, 
particularly MDD. An obvious need is to understand the importance and what are the 
alterations of ARs in brain areas affected by MDD, and what are the mechanisms 
behind those changes. 
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Chapter 2. Aims 
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Aims of this work: 
 
 
 
 
 To understand the differences in the brain localization, density and 
function of adenosine A1 and A2A receptors, between control subjects 
and suicide completers; 
 
 To evaluate if these modifications are accompanied by: 
 
o Synaptic imbalance, in brain areas affected by depression; 
 
o Astrocytic changes, in brain areas affected by depression. 
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Chapter 3. Materials and Methods 
 
 
 
  
  
Role of adenosine receptors in suicide 
18 
 
3.1 Materials / Reagents / Biological samples 
 
3.1.1 Reagents 
 
Table 2. Reagents and drugs used. 
Reagent Supplier 
1,4-bis(sulfanyl)butane-2,3-diol (DTT) Sigma-Aldrich (Portugal) 
2-[2-[bis(carboxylatomethyl)amino]ethyl-
(carboxylatomethyl)amino]acetate (EDTA) 
tetrasodium 
Sigma-Aldrich (Portugal) 
2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-
hydroxyethoxy)ethoxy]ethyl dodecanoate 
(Tween 20) 
Sigma-Aldrich (Portugal) 
2-(4-carboxyquinolin-2-yl)quinoline-4-carboxylic 
acid (BCA) kit 
Thermo scientific (USA) 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid (HEPES) 
Sigma-Aldrich (Portugal) 
2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol 
(Triton-X – 100) 
Sigma-Aldrich (Portugal) 
2,6-dibromo-4-[3-(3,5-dibromo-4-hydroxyphenyl)-
1,1-dioxo-2,1λ6-benzoxathiol-3-yl]phenol 
(bromophenol blue) 
Sigma-Aldrich (Portugal) 
2-amino-2-(hydroxymethyl)propane-1,3-diol 
(Trizma base) 
Sigma-Aldrich (Portugal) 
2-aminooxyacetic acid Sigma-Aldrich (Portugal) 
(2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-
5-(hydroxymethyl)oxolane-3,4-diol (CPA) 
Sigma-Aldrich (Portugal) 
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-
dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-
6-(hydroxymethyl)oxane-3,4,5-triol (sucrose) 
Sigma-Aldrich (Portugal) 
30% acrylamide/Bis solution Bio Rad (Portugal) 
3-[4-[2-[[6-amino-9-[(2R,3R,4S,5S)-5-
(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-
yl]amino]ethyl]phenyl]propanoic acid (CGS 21680) 
Tocris – Biogen (Spain) 
3-(cyclohexylamino)propane-1-sulfonic acid 
(CAPS) 
Sigma-Aldrich (Portugal) 
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(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-
tetrol (glucose) 
Sigma-Aldrich (Portugal) 
[14C]-U-glutamate PerkinElmer (USA) 
Ammonium persulfate (APS) Sigma-Aldrich (Portugal) 
Bovine serum albumin (BSA) Sigma-Aldrich (Portugal) 
Calcium chloride (CaCl2) Sigma-Aldrich (Portugal) 
Cocktail of proteases inhibitors (CLAP) Roche Diagnostics (Portugal) 
ECF Western blotting reagent GE Healthcare (United Kingdom) 
Hydrochloric acid (HCl) Sigma-Aldrich (Portugal) 
Magnesium chloride (MgCl2) Sigma-Aldrich (Portugal) 
Magnesium sulfate (MgSO4) Sigma-Aldrich (Portugal) 
Methanol Sigma-Aldrich (Portugal) 
Methylsulfinylmethane (DMSO) Sigma-Aldrich (Portugal) 
N,N,N',N'-tetramethylethane-1,2-diamine (TEMED) Sigma-Aldrich (Portugal) 
Percoll GE Healthcare (United Kingdom) 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich (Portugal) 
Potassium chloride (KCl) Sigma-Aldrich (Portugal) 
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich (Portugal) 
Propane-1,2,3-triol (glycerol) Sigma-Aldrich (Portugal) 
RNeasy Mini kit Qiagen – Izasa (Portugal) 
Scintillation liquid Zinsser Analytic (Germany) 
Sodium dodecyl sulfate (SDS) Bio Rad (Portugal) 
Sodium azide Sigma-Aldrich (Portugal) 
Sodium chloride (NaCl) Sigma-Aldrich (Portugal) 
Sodium hydrogen carbonate (NaHCO3) Sigma-Aldrich (Portugal) 
Sodium hydrogen phosphate (NaH2PO4
.H2O) Sigma-Aldrich (Portugal) 
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3.1.2 Antibodies 
 
Table 3. Primary antibodies for Western blot. 
Antibody Supplier Host Dilution Protein 
bands (kDa) 
Adenosine A1 receptor 
(A1R) 
Thermo Scientific 
#PA3-041A 
Rabbit 1:1000 37 
Adenosine A2A receptor 
(A2AR) 
Santa Cruz 
#SC-13937 
Rabbit 1:500 43 
β-actin 
Sigma 
#A5316 
Mouse 1:20000 42-43 
Glial fibrillary acidic protein 
(GFAP) 
Millipore 
#AB5804 
Rabbit 1:20000 50 
Postsynaptic density-95 protein 
(PSD-95) 
Sigma 
#P246 
Mouse 1:20000 95 
Synaptosomal-associated 
protein 25 
(SNAP-25) 
Sigma 
#S5187 
Mouse 1:20000 25 
Synaptophysin 
Sigma 
#S5768 
Mouse 1:20000 38-42 
Syntaxin 
Sigma 
#S0664 
Mouse 1:5000 35 
 
Table 4. Secondary antibodies for Western blot. 
2nd Antibody (anti species) Supplier Dilution 
Mouse 
GE Healthcare 
#NIF 1316 
1:20000 
Rabbit 
GE Healthcare 
#NIF 1317 
1:20000 
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3.1.3 Human samples 
Human brain samples were obtained at autopsies performed in the Instituto 
Nacional de Medicina Legal e Ciências Forenses, I. P. (INMLCF), in Coimbra. The 
tissue samples were collected by the pathologist Dr. Beatriz Silva with all procedures 
approved by the INMLCF and subject to the rules of the European Consortium of 
Nervous Tissues: BrainNet Europe II, to protect the identity of individual donors. 
 
 
Figure 2. Coronal slices from human brain samples. As reference point they used the 
mammillary bodies. (A) – Anterior (Before mamillary bodies). (B) - Posterior (After 
mamillary bodies). Images gently provided by Dr. Beatriz Silva from INMLCF. 
 
After being collected, the samples were placed in tubes, and were either rapidly 
frozen in liquid nitrogen and stored at -80ºC in a freezer, or they were placed on ice for 
functional assays. 
The study was performed in male subjects who died by suicide and in age-
matched non-suicide controls, who died by natural causes or accidents. To blind the 
individuals identification, a code-system of sequential numbers was created to match 
the brain samples collected to the individuals. Individuals excluded from the study were 
ones consuming medically-prescribed psychoactive drugs at the time of death; with 
neuro-pathological features of neurological disorders or psychiatric conditions such as 
addiction, eating disorders, schizophrenia or phobia; in coma or with artificial 
respiration before death. 
An important aspect in conducting postmortem research is the quality of the 
tissue, because unlike animal samples, human tissue conditions at death can’t be 
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controlled. Since the most sensitive indicator of tissue quality is ribonucleic acid (RNA) 
integrity number (RIN) and that there is a good correlation between RIN and the pH 
(Stan et al., 2006), the integrity of the tissue was validated by measurement of brain pH 
and RIN. However, neither postmortem interval (PMI), pH, nor RIN impact on protein 
concentrations in the human tissue, since even when RNA is degraded, protein levels 
remain stable (Stan et al., 2006). 
 
Table 5. Demographic characteristics and cause of death of individual cases of suicide 
completers and their respective controls. 
Number Sex Age Cause of death 
Postmortem 
Interval 
(hours) 
pH RIN 
Control 
or 
Suicide 
1 M 81 Hanging 39.6 6.55 6.7 Suicide 
2 M 66 Hanging 43.8 6.6 6.6 Suicide 
3 M 80 Hanging 45.8 6.49 5.5 Suicide 
4 M 41 Pulmonar hemorrhage 36.1 6.43 6.7 Control 
5 M 44 
Diazinon organophosphate 
poisoning 
20.9 6.3 5.7 Suicide 
6 M 17 Hanging 48.0 6.69 6.9 Suicide 
7 M 60 Hanging 28.1 6.48 6.8 Suicide 
8 M 65 Cardiopathy 52.3 5.81 ND Control 
9 M 81 Cardiopathy 16.5 5.96 ND Control 
10 M 60 Cardiopathy 76.8 6.44 ND Control 
11 M 21 Car accident 31.3 6.59 5.5 Control 
12 M 22 Car accident 32.7 6.64 6.3 Control 
13 M 53 Hanging 25.3 6.44 ND Suicide 
14 M 72 Cardiopathy 149.9 6.06 ND Control 
15 M 58 Hanging 20.5 6.42 ND Suicide 
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16 M 64 Burn * 6.65 6.8 Control 
17 M 60 Work accident 22.5 6.53 7.8 Control 
18 M 83 Cardiopathy 79.0 6.69 6.4 Control 
19 M 80 Accident 20.7 6.71 5.9 Control 
20 M 22 Hanging 34.6 6.53 5.9 Suicide 
21 M 32 Cardiopathy 29.8 6.69 7.8 Control 
22 M 76 Car accident 44.5 6.49 3.8 Control 
23 M 61 Accidental drowning 63.5 6.72 6.6 Control 
24 M 66 Hanging 32.0 6.6 6.9 Suicide 
25 M 54 Cardiopathy 11.1 6.38 4.3 Control 
26 M 71 Accidental fall 54.7 5.98 2.5 Control 
27 M 60 Hanging 46.7 6.71 5.9 Suicide 
28 M 62 Hanging 44.7 6.55 6.3 Suicide 
29 M 81 Car accident 32.9 6.2 6.1 Control 
30 M 63 Work accident 24.9 6.46 5.4 Control 
31 M 29 Hanging 27.35 6.6 6 Suicide 
32 M 62 Burning Accident 40.5 6.22 5.4 Control 
33 M 30 Hanging 68.5 6.63 6.2 Suicide 
* The brain was frozen; ND - Not determined. 
 
Table 6. Demographic characteristics of suicide completers and age-matched controls 
groups. 
 
Sex Age Postmortem Interval (hours) pH RIN 
Suicide M 51.9±7.0 34.6±3.6 6.5±0.04 6.5±0.2 
Control M 54.5±6.7 39.2±5.6 6.5±0.08 6.4±0.2 
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3.2 Methods 
 
3.2.1 pH determination 
Frozen brain tissue samples were homogenized manually by using a 
micropistill. The pH was measured with a pH electrode (Sentek), previously calibrated 
with 3 standards (pH= 4.00; pH = 7.00; pH = 10.00) at 4ºC (Monoramu et al., 2009). 
 
3.2.2 Total RNA extraction 
Samples stored at -80ºC were thawed and extraction of total RNA was 
performed. For this purpose, we used the RNeasy® Mini Kit (Qiagen), following the 
instructions provided by the manufacturer, with minor adaptations. 
Quantification of total RNA was performed at the end of extraction, as well as 
determination of RNA samples’ concentration and purity,, using a spectrophotometer 
(NanoDrop®, Thermo Scientific) through the ratio between the absorvances at 
wavelengths 260 and 280 nm (A260/A280). 
The samples were stored again in a freezer at -80 º C. 
 
3.2.3 RNA analysis 
The samples were run on an Agilent 2100 Bioanalyzer, which automatically 
calculates the sample RIN, through an algorithm based on the ribosomal peaks and the 
extent of RNA degradation products from the entire electropherogram and then assigns 
a score from 1 to 10 (Schroeder et al., 2006). RNA analysis was performed in 
collaboration with Dr. Manuela Grazina. 
 
3.2.4 Total extracts preparations 
Human brain samples were homogenized at 800 r.p.m. for 10-15 strokes in 
RIPA buffer (50 mM Tris, 150 mM NaCl, 1% IGEPA (NP-40), 0.5% sodium 
deoxycholate, 1 mM EDTA, 0.1% SDS), supplemented with CLAP, 0.1 mM DTT and 
0.1 mM PMSF, and then sonicated for at least 15 min at 4ºC. The samples were stored 
at -20ºC until further use. 
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3.2.5. Human synaptosomes isolation 
Synaptosomes are re-sealed, functional nerve terminals, which were separated 
from their axons and postsynaptic connections. A synaptosomal preparation encloses 
all common neuronal content, including cytoplasm, synaptic vesicles and mitochondria, 
with low presence of synaptic and glial plasma membranes and extrasynaptosomal 
mitochondria. Their function closely resembles nerve terminals in vivo, allowing the 
study of neurotransmitters release. (Dunkley et al., 1986, 2008) 
 
3.2.5.1 Human synaptosomes isolation in a discontinuous Percoll gradient 
Using our group know-how in rodents (Rebola et al., 2005; Canas et al., 2009; 
Gomes et al., 2009) we optimized the purification of nerve terminals from the human 
brain using an adapted discontinuous Percoll gradient protocol (Dunkley et al., 1986, 
2008). 
Human fresh brain tissue, from a particular brain region, was homogenized in a 
sucrose solution (0.32 M sucrose, 1 mM EDTA and 10 mM Tris pH 7.4, at 4ºC) at 800 
r.p.m. for 10-15 strokes. 
The homogenates were centrifuged at 1000 g for 10 min at 4º C (Avanti J-26 
XPI centrifuge, rotor JA-25-50), supernatants collected and further centrifuged at 20000 
g for 20 min at 4ºC (Avanti J-26 XPI centrifuge, rotor JA-25-50). Supernatants were 
discarded and pellets resuspended in the sucrose solution. This suspension was slowly 
and carefully placed on top of a discontinuous Percoll gradient, previously prepared.  
The gradient was built in a tube as follow, from bottom to top: 3 ml of a 23% 
(v/v) Percoll solution, 5 ml of a 10% (v/v) Percoll solution and 3 ml of a 3% (v/v) Percoll 
solution. Percoll solutions were previously prepared in the sucrose solution and 
maintained on ice until use. 
 
Figure 3. Representation of the discontinuous Percoll gradient (adapted from Dunkley 
et al., 2008). 
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The gradients were centrifuged at 16000 g for 20 min at 4ºC, without 
deceleration (Avanti J-26 XPI centrifuge, rotor JA-25-50). Synaptosomes were 
collected between the 10% (v/v) and 23% (v/v) Percoll layers and diluted in 15 ml of 
HEPES buffered medium (HBM) without calcium (140 mM NaCl, 5 mM KCl, 5 mM 
NaHCO3, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 10 mM Glucose and 10 mM HEPES, pH 
7.4). After centrifugation at 22000 g for 11 min at 4º C, free-moving pellets were 
collected, resuspended in HBM and centrifuged at 11000 g for 11 min, at 4ºC. Finally, 
synaptosomal pellets were resuspended in RIPA buffer supplemented with CLAP, 0.1 
mM DTT and 0.1 mM PMSF, and stored, at -20ºC until further use for protein 
quantification. 
 
3.2.5.2 P2 crude synaptosomal fraction preparation 
Human fresh brain tissue, from a particular brain region, was homogenized in a 
sucrose solution (0.32 M sucrose; 1 mM EDTA; 10 mM HEPES, pH 7.4 at 4ºC) at 800 
r.p.m. for 10-15 strokes. 
The homogenates were centrifuged at 5000 g for 5 min (eppendorf centrifuge). 
The supernatant was collected and centrifuged at 14000 g for 10 min (eppendorf 
centrifuge) to obtain the pellet that represents P2 crude synaptosomal fraction. This 
preparation was then used for [14C]Glutamate release assay. 
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3.2.6 Subsynaptic fractionation 
A fractionation method, previously described (Phillips et al., 2001) and used by 
our group (Rebola et al., 2005), was performed to allow the separation of extrasynaptic, 
presynaptic active zone and postsynaptic active zone fractions from synaptosomes. 
With this technique, the accessibility of antibodies to epitopes located at synapses is 
enhanced by the solubilization of different subsynaptic components, which disrupt the 
dense protein matrix (Phillips et al., 2001; Rebola et al., 2005).  
The efficiency of separation is demonstrated by the capability to restore the 
immunoreactivity for the different markers in the several fractions: SNAP-25 in the 
presynaptic active zone, PSD-95 in the postsynaptic density and synaptophysin 
(vesicle protein not tightly linked to synaptic scaffold) outside the active zone 
(extrasynaptic fraction). The initial synaptosomal fraction (synap), from where 
fractionation began, was used as an internal control (Rebola et al., 2005). 
 
Brain samples, from the different regions, were homogenized in Isolation Buffer 
(IB, containing: 0.32 M Sucrose, 0.1 mM CaCl2, 1 mM MgCl2, CLAP and 0.1 mM 
PMSF). The homogenate was re-suspended in 2 M sucrose and 0.1 mM CaCl2 and the 
obtained mixture (1.25 M sucrose) gently agitated. This suspension was separated into 
UltraclearTM tubes and 1 M sucrose solution, containing 0.1 mM CaCl2, was carefully 
added in order to allow the formation of a gradient. The tubes were equilibrated with IB 
solution and centrifuged at 100000 g at 4º C, for 3 h (Beckman Coulter – Optima CL – 
100XP DU ultracentrifuge, rotor SW41Ti).  
The IB solution and the myelin layer, present at the interface IB/1 M sucrose, 
were removed and the synaptosomes were collected at the interface the 1 M and 1.25 
M sucrose. 
Synaptosomes fraction was diluted in 10 times its volume with IB and 
centrifuged at 15000 g for 30 min (Avanti J-26 XPI centrifuge, rotor JA-25-50).  
The pellet was re-suspended with IB solution, and part of the obtained 
supernatant, correspondent to the total synaptosomal fraction (initial synaptosomal 
fraction from where the fractionation began) was centrifuged at maximum speed for 5 
min (eppendorf centrifuge) and the obtained pellet re-suspended with 5% SDS and 
stored at -20ºC, to be used as an internal control of the fractionation. 
The remaining suspension was diluted 10 times with pre-cooled 0.1 mM CaCl2. 
An equal volume of solubilization buffer 2x (2% Triton X-100, 40 mM Tris, pH 6.0) was 
added to the suspension. 
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The mixture was incubated for 30 min on ice with mild agitation and then 
centrifuged at 40000 g for 30 min, at 4ºC (Avanti J-26 XPI centrifuge, rotor JA-25-50). 
The pellet represents the synaptic junctions and the supernatant the 
extrasynaptic fraction. The extrasynaptic fraction was then decanted and proteins 
precipitated with six volumes acetone at -20º C, overnight. 
The synaptic junctions pellet was washed with solubilization buffer 1x (20 mM 
Tris, 1% Triton X-100, pH 6.0) and re-suspended in 10 volumes of solubilization buffer 
1x (20 mM Tris, 1% Triton X-100, pH 8.0).  
This mixture was incubated for 30 min on ice, with mild agitation, and then 
centrifuged at 40000 g for 30 min at 4º C (Avanti J-26 XPI centrifuge, rotor JA-25-50). 
The obtained supernatant corresponds to the presynaptic active zone and was 
processed as described for the extrasynaptic fraction. The insoluble pellet represents 
the postsynaptic density, which was resuspended in a minimal volume of 5% SDS with 
0.1 mM PMSF and stored overnight at -20ºC. 
The extra and presynaptic fractions were pelleted by centrifugation at 18000 g 
for 30 min at -15º C (Sorvall RC6, rotor SS34), solubilized in 5% SDS with 0.1 mM 
PMSF and then stored at -20º C. 
 
 
Figure 4. Schematic representation of the subsynaptic components that are expected 
to be enriched in each of the fractions isolated (adapted from Phillips et al., 2001). 
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3.2.7 Protein quantification by the BCA method 
Protein concentration determination was performed using the BCA protein 
assay kit (Pierce® BCA Protein Assay, Thermo Scientific) using bovine serum albumin 
(BSA) as a protein standard.  
The absorbance was read at 570 nm in a spectrophotometer. 
The standard curve was then used to calculate the protein concentration in 
μg/μL. 
 
3.2.8 Western blot 
After determination of protein concentration, samples protein content was 
denatured in 6x sample buffer (500 mM Tris/SDS buffer pH 6.8, 600 mM DTT, 10.3% 
SDS, 30% glycerol and 0.012% bromophenol blue) for 20 min at 70°C, and stored at 
−20°C until use.  
Gel electrophoresis was carried out in a 10% polyacrylamide resolving gel with 
4% polyacrylamide stacking gel and proteins were then transferred to previously 
activated polyvinylidene difluoride (PVDF) membranes for 2 h, at 4º C. The membranes 
were then blocked for 1 h, by immersing them in 5% milk in TBS-T (TBS 1x+ 0.1% 
Tween 20), on a  shaker at room temperature, and then incubated in the diluted 
primary antibody, in 1% milk in TBS-T, at 4°C overnight. 
After washing with TBS-T, the membranes were then incubated with the 
corresponding alkaline phosphatase-linked anti-species secondary antibody, diluted in 
1% milk in TBS-T, for 2 h at room temperature. To perform immunodetection, 
membranes were washed in TBS-T, and revealed by an enhanced chemifluorescence 
(ECF) substrate (AmershamTM ECF substrate for Western Blotting, GE Healthcare) and 
visualized in a VersaDoc system (Bio Rad). 
 
Table 7. Polyacrylamide gel formulation. 
Gel Formulation (1 Gel: 1.5 mm) 10% 4% 
Tris-buffer, 1.5 M, pH 8.8 (Resolving gel) 2.5 ml - 
Tris-buffer, 0.5 M, pH 6.8 (Stacking gel) - 2.5ml 
Acrylamide 30 % (Bio-Rad) 3.3 ml 1.3 ml 
Water 4.1 ml 6.1 ml 
SDS 10% (Sigma-Aldrich) 100 µl 100 µl 
TEMED (Sigma-Aldrich) 5 µl 10 µl 
APS 20 % (freshly prepared, diluted in water) 100 µl 100 µl 
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3.2.9 Stripping and reprobing of membranes 
To remove the ECF substrate, membranes were submerged in 40% methanol and 
were incubated at room temperature (RT) for 30 min with agitation. Afterwards, the 
membranes were rinsed twice in TBS-T for 10 min. 
For antibodies removal, the membranes were submerged twice in stripping 
solution (15 g/L glycine, 10 mL/L Tween 20, 1 g/L SDS, pH 2.2) for 30 min, and 
washed twice in TBS-T for 10 min. 
The membranes were then blocked by immersing them in 5% milk in TBS-T for 
1 h at RT with agitation, and incubated overnight with primary antibody and proceeded 
as in the Western blot protocol. 
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3.2.10 [14C]Glutamate release from synaptosomes 
P2 crude synaptosomal fraction were diluted with Krebs’ solution (113 mM 
NaCl; 3mM KCl; 1.2 mM MgSO4; 1.2 mM KH2PO4; 2.5 mM CaCl2; 10 mM glucose; 15 
mM HEPES, pH 7.4), containing 100 µM aminooxyacetic acid. In order to prevent 
[14C]glutamate metabolism, aminooxyacetic acid, a general inhibitor of pyridoxal 
phosphate (PlP)-dependent enzymes, including glutamate decarboxylase, was 
included in all solutions.  
Synaptosomes were then incubated with 20 µM [14C]-U-glutamate for 10 min, at 
37ºC. A 116-micro volume chamber perfusion setup was filled with the preloaded 
synaptosomes which were trapped by one layer of Whatman GF/C filters (GE 
Healthcare). The filters were then superfused continuously at a rate of 0.7 mL/min until 
the end of the experiment, at 37ºC. 
After the 10 min washout, 2 min content were collected in scintillation vials 
containing 2.5 mL of scintillation liquid, and the filters with the synaptosomes were also 
harvested to obtain the total radioactivity content. 
Synaptosomes were stimulated twice (S1, first stimulation period; S2, second 
stimulation period) with 30 mM KCl within a 10 min interval. 
100 µM of Adenosine A1 receptor agonist CPA or 30 µM of Adenosine A2A 
receptor agonist CGS 21680 were bath applied in the Krebs’ solution before the S2 and 
superfused until the end of the experiment. DMSO (0.1% v/v) was used as control 
solution. 
Vials content was assayed for the [14C] content by a label protocol using a 
Tricarb β-counter (PerkinElmer), and disintegration/minute (dpm) values were 
expressed as a fractional release (FR%), i.e. the percent of actual content in the 
effluent as a function of the total synaptosomal content. For instance, if 10 units of 
radioactivity leave the chamber in a 2-min period and the filter retained 90 units, this 
calculates as 10 units left 90+10 original units, i.e. as 10 FR%. 
 
Figure 5. Representation of a release experiment.  
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3.3. Data presentation 
 
 Results are presented as mean ± SEM. Values of the number of experiments (n) is 
indicated in figure legends. Data is presented in percentage of total extracts or age-       
-matched controls. Either a one sample t-test compared with the hypothetical value of 
100 or a one-way analysis of variance (ANOVA) followed by post-hoc Newman-Keuls 
test, was used  to define statistical differences between means, which were considered  
significant for a p < 0.05.  
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Chapter 4. Results 
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4.1 Brodmann area 25 (BA25) 
 
4.1.1 Nerve terminals validation 
To validate this nerve terminals (NT) preparation, the relative amount of 
synaptic and glial markers was compared in NT and in total extracts (TE) of the same 
sample, by Western blot analysis. 
We observed an increase in the density of synaptosomal-associated protein 25 
(SNAP-25) (134.0% ± 40.0%, n=5), synaptophysin (152.2% ± 41.1%, n=6) and 
syntaxin (87.2% ± 20.5%, n=6) in NT preparation compared to TE (Figure 6). 
We also observed a decrease in the density of fibrillary acidic protein (GFAP) in 
NT (61.4% ± 3.7%, n=10) than in TE (Figure 6). 
These results indicate that the synaptic markers SNAP-25, synaptophysin and 
syntaxin are enriched in BA25 nerve terminals as compared with total extracts, and as 
expected there is an enrichment of GFAP density in total extracts when compared with 
the nerve terminals preparation. These results validate human nerve terminals isolation 
in BA25. 
 
 
Figure 6. Validation of nerve terminals preparation from BA25 - using several synaptic 
markers (SNAP-25, synaptophysin and syntaxin) and a glial marker (GFAP). The data 
is presented in percentage of total extracts. Data are mean±SEM of n=5-10. * p < 0.05, 
one sample t-test compared with the hypothetical value of 100. 
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4.1.2 Adenosine receptors localization 
To comprehend the normal localization of adenosine A1 receptors (A1R) and 
adenosine A2A receptors (A2AR) we used Western blot analysis, comparing the relative 
abundance of A1R and A2AR in TE and in NT of BA25 of the same sample. 
We observed an increase in the imumunoreactivity of both A1R (42.8 % ± 9.5%, 
n=15) and A2AR (42.7 % ± 15.8%, n=6)  in NT preparation compared to TE (Figure 7). 
 
 
Figure 7. A1R and A2AR enrichment in BA25 nerve terminals. (A) A1R and A2AR are 
enriched in nerve terminals. (B) Representative Western blot of the A1R and A2AR 
levels in both preparations. (C) Representative Western blot of the β-actin density 
(control for protein loading). The data is presented in percentage of total extracts. Data 
are mean±SEM of n=6-15. * p < 0.05, one sample t-test compared with the hypothetical 
value of 100. 
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4.1.3 Adenosine receptors subsynaptic localization 
After testing if there was an enrichment of A1R and A2AR in NT, we went to 
refine the information about their subsynaptic localization. It was analyzed if A1R and 
A2AR are differently distributed in the different subsynaptic fractions. Therefore, we 
used a fractionation procedure, previously validated by our group (Rebola et al., 2005), 
which allows an effective separation of the non-active zone, presynaptic active zone 
and post-synaptic fractions (Rebola et al., 2005; Phillips et al., 2001). 
4.1.3.1 A1 receptor 
The data presented in Figure 8 shows that A1R is located in all fractions of 
synaptosomes.  
 
 
Figure 8. A1R is present in all synaptic fractions of BA25. (A) BA25 subsynaptic levels 
of A1R. (B) Representative Western blot of the subsynaptic distribution of A1R. (C) The 
efficiency of the fractionation is illustrated by the ability to recover the immunoreactivity 
for SNAP-25 in the presynaptic active zone (PRE), PSD-95 in the postsynaptic density 
(POST) and synaptophysin in the extrasynaptic fraction (EXTRA). The data are present 
as mean±SEM of n=3, one-way ANOVA. 
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4.1.3.1 A2A receptor 
The data presented in Figure 9 shows that A2AR is mainly located in the 
extrasynaptic fraction of nerve terminals, although it is also present in the presynaptic 
density at a considerably lower level.  
 
 
Figure 9. A2AR is mostly present in BA25 extrasynaptic fraction. (A) BA25 subsynaptic 
levels of A2AR. (B) Representative Western blot of the subsynaptic distribution of A2AR 
(C) The efficiency of the fractionation is illustrated by the ability to recover the 
immunoreactivity for SNAP-25 in the presynaptic active zone (PRE), PSD-95 in the 
postsynaptic density (POST) and synaptophysin in the extrasynaptic fraction (EXTRA). 
Data are mean±SEM of n=3. * p < 0.05, one-way ANOVA followed by post-hoc 
Newman-Keuls test. 
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4.1.4 Synaptic markers in suicide 
In this part of the study, we mainly focus on determining the changes of different 
synaptic markers in the BA25, namely SNAP-25, synaptophysin and syntaxin in suicide 
completers in comparison with age-matched controls, in NT. This was assessed by 
Western blot analysis, and the immunoreactivity of each band was normalized with β-
actin. 
In BA25 nerve terminals, there was a decrease in SNAP-25 density (43.9% ± 
10.9%, n=10) with suicide (Figure 10). 
No significant differences were found, in the immunoreactivity of synaptophysin 
(96.9% ± 11.6%, n=9) and syntaxin (93.4% ± 9.0%, n=9), in the suicide group 
compared with age-matched controls (Figure 10). 
 
 
Figure 10. Down-regulation of SNAP-25 density with suicide in nerve terminals from 
BA25. (A) SNAP-25 density decreases with suicide in nerve terminals. (B) 
Representative Western blot of the SNAP-25 levels in the suicide and control samples. 
(C) Representative Western blot of the β-actin density (control for protein loading). The 
data is presented in percentage of control nerve terminals. Data are mean±SEM of 
n=9-10, * p<0.05, one sample t-test compared with the hypothetical value of 100. 
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4.1.5 Astrocytes in suicide 
Additionally, we also tested for astrocytic marker to gauge for changes of 
astrocytes in suicide completers, in TE. This was assessed by Western blot analysis, 
and the immunoreactivity of each band was normalized with β-actin. 
In BA25, there was a decrease of GFAP density (39.2% ± 13.7%, n=5) in 
suicide completers, when compared with age-matched controls (Figure 11). 
 
 
Figure 11. Down-regulation of GFAP density with suicide in TE from BA25. (A) GFAP 
density decreases with suicide in the total extracts from BA25. (B) Representative 
Western blot of the GFAP levels in the suicide and control samples. (C) Representative 
Western blot of the β-actin density (control for protein loading). The data is presented in 
percentage of control total extracts. Data are mean±SEM of n=5. * p<0.05, one sample 
t-test compared with the hypothetical value of 100. 
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4.1.6 Adenosine receptors in suicide 
After mapping A1R and A2AR localization and density in BA25, we went to try to 
understand if there were any changes of these receptors with suicide. 
 
4.1.6.1 A1 receptor 
The relative abundance of A1R in both TE and NT from suicide completers, in 
comparison to samples from age-matched controls, was assessed by Western blot 
analysis. The immunoreactivity of each band was normalized with β-actin. 
No significant differences were found, in the BA25 A1R immunoreactivity, in 
both TE (104.4% ± 6.5%, n=6) and NT (90.6% ± 17.6%, n=6) preparations, in the 
suicide group when compared with the control group (Figure 12). 
 
 
Figure 12. No changes of A1R densities with suicide in BA25. (A) A1R densities do not 
change with suicide in both preparations. (B) Representative Western blot of the A1R 
levels in the suicide and control samples. (C) Representative Western blot of the β-
actin density (control for protein loading). The data is presented in percentage of the 
respective age-matched control. Data are mean±SEM of n=6, one sample t-test 
compared with the hypothetical value of 100.  
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4.1.6.1 A2A receptor 
The relative abundance of A2AR in both TE and NT from suicide completers, in 
comparison to samples from age-matched controls, was assessed by Western blot 
analysis. The immunoreactivity of each band was normalized with β-actin. 
In BA25, there was an up-regulation A2AR density in TE (48.4% ± 20.4%, n=9), with 
suicide (Figure 13). 
No significant differences were found, in the BA25 A2AR density in NT (117.6% 
± 13.8%, n=9) from suicide completers when compared with age-matched controls 
(Figure 13). 
 
 
Figure 13. Up-regulation of A2AR density with suicide in total extracts from BA25. (A) 
A2AR density increase with suicide in the total extracts. A2AR density does not change 
with suicide in nerve terminals. (B) Representative Western blot of the A2AR levels in 
the suicide and control samples. (C) Representative Western blot of the β-actin density 
(control for protein loading). The data is presented in percentage of respective age-
matched control. Data are mean±SEM of n=9. * p<0.05, one sample t-test compared 
with the hypothetical value of 100. 
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4.1.7 Conclusion 
In conclusion, by comparing the levels of A1R and A2AR in BA25 nerve terminals 
and total extracts, it was found that both receptors are enriched in BA25 nerve 
terminals. We then refined the information on ARs subsynaptic localization, using a 
fractionation method, and it was observed that A2AR are mainly located outside the 
active zone and A1R are present in all synaptic fractions. 
Synaptic and astrocytic changes present in BA25 of suicide completers were 
studied and was observed a down-regulation of both SNAP-25 and GFAP. 
An up-regulation of A2AR density in total extracts was observed in suicide 
completers when compared with age-matched controls. 
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4.2 Medial caudate nucleus (MC) 
 
4.2.1 Nerve terminals validation 
As for the previously studied area, the relative amount of synaptic and glial 
markers was compared in TE and in NT of the same sample, by Western blot analysis, 
in order to validate NT preparation in medial caudate nucleus (MC). 
We observed an increase in the density of SNAP-25 (39.0% ± 15.4%, n=8), 
synaptophysin (29.1% ± 5.8%, n=8) and postsynaptic density protein 95 (PSD-95) 
(21.8% ± 7.2%, n=10) in NT preparation compared to TE (Figure 14). 
We also observed a decrease in the density of GFAP in NT (38.6% ± 11.6%, 
n=5) than in TE (Figure 14). 
These results indicate that the synaptic markers SNAP-25, synaptophysin and 
PSD-95 are enriched in MC nerve terminals as compared with total extracts and, as 
expected, there is an enrichment of GFAP density in total extracts when compared with 
the nerve terminals preparation. These results then validate human nerve terminals 
isolation in MC. 
 
 
Figure 14. Validation of nerve terminals preparation from MC – using several synaptic 
markers (SNAP-25, synaptophysin and PSD-95) and a glial marker (GFAP). The data 
is presented in percentage of total extracts. Data are mean±SEM of n=5-10. * p<0.05 
one sample t-test compared with the hypothetical value of 100. 
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4.2.2 Adenosine receptors localization 
As in BA25, we first went to comprehend the normal localization of A1R and 
A2AR receptors. Using Western blot analysis, the relative abundance of A1R and A2AR 
was compared in TE and in NT of MC of the same sample. 
We observed an increase in the immunoreactivity of both A1R (27.1 % ± 10.5%, 
n=11) and A2AR (23.7% ± 7.1%, n=11) in NT preparation compared to TE (Figure 15). 
 
 
Figure 15. A1R and A2AR enrichment in nerve terminals from MC. (A) A1R and A2AR 
are enriched in nerve terminals. (B) Representative Western blot of the A1R and A2AR 
levels in both preparations. (C) Representative Western blot of the β-actin density 
(control for protein loading). The data is presented in percentage of total extracts. Data 
are mean±SEM of n=11. * p<0.05, one sample t-test compared with the hypothetical 
value of 100. 
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4.2.3 Adenosine receptors subsynaptic localization 
After testing if there is a enrichment of A1R and A2AR in NT, we went to refine 
the information on their subsynaptic localization. It was analyzed how A1R and A2AR 
are distributed in the different subsynaptic fractions. Therefore, we used a fractionation 
procedure (Phillips et al., 2001), previously validated by our group (Rebola et al., 
2005). 
 
4.2.3.1 A1 receptor 
The results presented in Figure 16 are preliminary results (n=2), showing that 
A1R is located in all fractions of synaptosomes. 
 
 
Figure 16. A1R is present is in all synaptic fractions of MC. (A) MC subsynaptic levels 
of A1R. (B) Representative Western blot of the subsynaptic distribution of A1R. (C) The 
efficiency of the fractionation is illustrated by the ability to recover the immunoreactivity 
for SNAP-25 in the presynaptic active zone (PRE), PSD-95 in the postsynaptic density 
(POST) and synaptophysin in the extrasynaptic fraction (EXTRA). Data are preliminary 
results (n=2). 
 
 
 
Role of adenosine receptors in suicide 
46 
 
4.2.3.2 A2A receptor 
The data presented in Figure 17 shows that A2AR is mainly located in the 
extrasynaptic fraction of synaptosomes, although it is also present in the pre- and 
postsynaptic densities at a lower level.  
The results presented are preliminary results (n=2). 
 
 
Figure 17. A2AR are mainly located outside the active zone in MC. (A) MC subsynaptic 
levels of A2AR. (B) Representative Western blot of the subsynaptic distribution of A2AR 
(C) The efficiency of the fractionation is illustrated by the ability to recover the 
immunoreactivity for SNAP-25 in the presynaptic active zone (PRE), PSD-95 in the 
postsynaptic density (POST) and synaptophysin in the extrasynaptic fraction (EXTRA). 
Data are preliminary results (n=2). 
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4.2.4 Synaptic markers in suicide 
We tried to determine the changes of different synaptic markers in the MC, 
namely SNAP-25, synaptophysin and a post-synaptic marker of glutamatergic 
synapses (PSD-95) in suicide completers in comparison with age-matched controls, in 
NT. This was assessed by Western blot analysis, and the immunoreactivity of each 
band was normalized with β-actin. 
In MC nerve terminals, there was a decrease in SNAP-25 density (16.3% ± 
6.3%, n=6) with suicide (Figure 18). 
No significant differences were found, in the immunoreactivity of synaptophysin 
(99.9% ± 5.5%, n=5) and PSD-95 (99.5% ± 12.0%, n=6), in the suicide group when 
compared with non-suicide controls (Figure 18). 
 
 
Figure 18. Down-regulation of SNAP-25 density with suicide in nerve terminals from 
MC. (A) SNAP-25 density decreases with suicide in nerve terminals. (B) 
Representative Western blot of the SNAP-25 levels in the suicide and control samples. 
(C) Representative Western blot of the β-actin density (control for protein loading). The 
data is presented in percentage of control nerve terminals. Data are mean±SEM of 
n=9-10. * p<0.05, one sample t-test compared with the hypothetical value of 100. 
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4.2.5 Astrocytes in suicide 
We also tested for an astrocytic marker, in MC, to determine if there were any 
changes of astrocytes in suicide completers, in TE. This was assessed by Western blot 
analysis, and the immunoreactivity of each band was normalized with β-actin. 
In MC, there were no significant differences in GFAP density (120.2% ± 17.0%, 
n=5) of suicide completers, when compared with age-matched controls (Figure 19). 
 
 
Figure 19. GFAP density levels do not change with suicide in MC total extracts. The 
data is presented in percentage of control total extracts. Data are mean±SEM of n=5, 
one sample t-test compared with the hypothetical value of 100. 
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4.2.6 Adenosine receptors in suicide 
After mapping ARs in MC, we also went to try to understand if there are 
variations of both A1R and A2AR with suicide. 
 
4.2.6.1 A1 receptor 
The relative abundance of A1R in both TE and NT from suicide completers, in 
comparison to samples from age-matched controls, was assessed by Western blot 
analysis. The immunoreactivity of each band was normalized with β-actin. 
In MC, there was an up-regulation of A1R density in TE (31.8% ± 12.0%, n=6), 
with suicide (Figure 20). 
No significant differences were found, in the MC A1R density in NT (108.1% ± 
17.4%, n=6) from suicide completers when compared with age-matched controls 
(Figure 20). 
 
 
Figure 20. A1R up-regulation with suicide in the TE from MC. (A) A1R density increase 
with suicide in the TE from MC by Western blot. A1R density does not change with 
suicide in the NT from MC. (B) Representative Western blot of the A1R levels in the 
suicide and control samples. (C) Representative Western blot of the β-actin density 
(control for protein loading). The data is presented in percentage of the respective age-
matched control. Data are mean±SEM of n=6. * p<0.05, one sample t-test compared 
with the hypothetical value of 100. 
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4.2.6.2 A2A receptor 
The relative abundance of A2AR in both TE and NT from suicide completers, in 
comparison to samples from age-matched controls, was assessed by Western blot 
analysis. The immunoreactivity of each band was normalized with β-actin. 
No significant differences were found, in the MC A2AR immunoreactivity, in both 
TE (112.5% ± 8.2%, n=5) and NT (107.0% ± 5.2%, n=4) preparations, in the suicide 
group when compared with the control group (Figure 21). 
 
 
Figure 21. No changes in A2AR density with suicide in the nerve terminals and total 
extracts from MC. (A) A2AR densities do not change with suicide in both, nerve 
terminals and total extracts, preparations. (B) Representative Western blot of the A2AR 
levels in the suicide and control samples. (C) Representative Western blot of the β-
actin density (control for protein loading). The data is presented in percentage of the 
respective age-matched controls. Data are mean±SEM of n=4-5, one sample t-test 
compared with the hypothetical value of 100. 
 
  
Role of adenosine receptors in suicide 
51 
 
4.2.7 Conclusion 
So, we can conclude that, such as in BA25, both A1R and A2AR, in MC, are 
enriched in the nerve terminals. We refined the information on their subsynaptic 
localization, using a fractionation method, and it was observed that A2AR are mainly 
located outside the active zone and A1R are present in all synaptic fractions. 
We also provided the information about the synaptic changes present in MC of 
suicide completers, showing down-regulation of SNAP-25 density levels with suicide, 
similar to BA25. 
An up-regulation of A1R density in total extracts was observed in suicide 
completers when compared with age-matched controls. 
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4.3 Posterior caudate nucleus (PC) 
 
4.3.1 Nerve terminals validation 
To validate NT preparation from posterior caudate nucleus (PC), the relative 
amount of synaptic and glial markers was compared in TE and in NT of the same 
sample, by Western blot analysis. 
We observed an increase in the density of SNAP-25 (35.2% ± 10.0%, n=10), 
synaptophysin (79.7% ± 25.9%, n=13) and PSD-95 (57.8% ± 20.4%, n=13) in NT 
preparation compared to TE (Figure 22). 
We also observed a decrease in the density of GFAP in NT (41.0% ± 6.3%, 
n=10) compared with TE (Figure 22). 
These results indicate that the synaptic markers SNAP-25, synaptophysin and 
PSD-95 are enriched in PC nerve terminals as compared with total extracts, and that 
the astrocytic marker GFAP is enriched in PC total extracts. These results validate 
human nerve terminals isolation in PC. 
 
 
Figure 22. Validation of nerve terminals preparation from PC - using several synaptic 
markers (SNAP-25, synaptophysin and PSD-95) and a glial marker (GFAP). The data 
is presented in percentage of total extracts. Data are mean±SEM of n=10-13. * p<0.05, 
one sample t-test compared with the hypothetical value of 100. 
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4.3.2 Adenosine receptors localization 
To comprehend the normal localization of A1R and A2AR receptors we used 
Western blot analysis, comparing the relative abundance of A1R and A2AR in TE and in 
NT of PC of the same sample. 
We observed an increase in the imumunoreactivity of both A1R (23.3% ± 8.9%, 
n=11) and A2AR (65.5% ± 18.9%, n=11) in NT preparation compared to TE (Figure 23). 
 
 
Figure 23. A1R and A2AR enrichment in nerve terminals from PC. (A) A1R and A2AR are 
enriched in nerve terminals. (B) Representative Western blot of the A1R and A2AR 
levels in both preparations. (C) Representative Western blot of the β-actin density 
(control for protein loading). The data is presented in percentage of total extracts. Data 
are mean±SEM of n=11. * p<0.05, one sample t-test compared with the hypothetical 
value of 100. 
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4.3.3 Synaptic markers in suicide 
We then focused on determining the changes of different synaptic markers in 
the PC, namely SNAP-25, synaptophysin and PSD-95, in suicide completers in 
comparison with age-matched controls. This was assessed by Western blot analysis 
and the immunoreactivity of each band was normalized with β-actin. 
No significant differences were found, in the immunoreactivity of SNAP-25 
(79.4% ± 9.8%, n=5) and synaptophysin (99.7% ± 8.8%, n=5), in the suicide group 
when compared with age-matched controls (Figure 24). 
In PC nerve terminals, there was an decrease in PSD-95 levels (35.6% ± 
10.4%, n=6) in the suicide completers group when compared with age-matched 
controls (Figure 24).  
 
 
Figure 24. Down-regulation of PSD-95 density with suicide in nerve terminals from PC. 
(A) PSD-95 density decreases with suicide in nerve terminals. (B) Representative 
Western blot of the PSD-95 levels in the suicide and control samples. (C) 
Representative Western blot of the β-actin density (control for protein loading). The 
data is presented in percentage of control nerve terminals. Data are mean±SEM of 
n=5-6. * p<0.05, one sample t-test compared with the hypothetical value of 100. 
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4.3.4 Astrocytes in suicide 
In this brain area, we also tested for astrocytic changes in suicide completers. 
The relative abundance of GFAP in TE from suicide completers, in comparison 
to samples from age-matched controls was assessed by Western blot analysis. The 
immunoreactivity of each band was normalized with β-actin. 
In PC, GFAP density do not change with suicide (73.7% ± 23.3%, n=6), inTE 
(Figure 25). 
 
 
Figure 25. GFAP density levels do not change with suicide in total extracts of PC. The 
data is presented in percentage of control total extracts. Data are mean±SEM of n=5, 
one sample t-test compared with the hypothetical value of 100. 
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4.3.5 Adenosine receptors in suicide 
After observing A1R and A2AR localization in PC, we went to try to understand 
the differences between suicide completers and non-suicidal controls. 
 
4.3.5.1 A1 receptor 
The relative abundance of A1R in both nerve terminals and total extracts from 
suicide completers, in comparison to samples from age-matched controls was 
assessed by Western blot analysis. The immunoreactivity of each band was 
normalized with β-actin. 
No significant differences were found, in the PC A1R immunoreactivity in TE 
(96.7% ± 12.9%, n=6) preparations, in the suicide group compared with control group 
(Figure 26). 
In PC, there was a down-regulation of A1R in NT (35.0% ± 10.4%, n=5), with 
suicide (Figure 26). 
 
  
Figure 26. Down-regulation of A1R density with suicide in nerve terminals from PC. (A) 
A1R density do not change with suicide in total extracts and A1R density decrease with 
suicide in nerve terminals. (B) Representative Western blot of the A1R levels in the 
suicide and control samples. (C) Representative Western blot of the β-actin density 
(control for protein loading). The data is presented in percentage of the respective age-
matched controls. Data are mean±SEM of n=5-6. * p<0.05, one sample t-test 
compared with the hypothetical value of 100. 
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4.3.5.2 A2A receptor 
The relative abundance of A2AR in both TE and NT from suicide completers, in 
comparison to samples from age-matched controls, was assessed by Western blot 
analysis. The immunoreactivity of each band was normalized with β-actin. 
In PC, there was an up-regulation A2AR density in TE (29.9% ± 11.2%, n=6), 
with suicide (Figure 27). 
No significant differences were found, in PC A2AR density in NT (92.1% ± 
10.1%, n=5) from suicide completers when compared with age-matched controls 
(Figure 27). 
 
 
Figure 27. Up-regulation of A2AR with suicide in total extracts from PC. (A) A2AR 
density increases in total extracts and do not change in the nerve terminals with 
suicide. (B) Representative Western blot of the A2AR levels in the suicide and control 
samples. (C) Representative Western blot of the β-actin density (control for protein 
loading). The data is presented in percentage of the respective age-matched controls. 
Data are mean±SEM of n=5-6, * p<0.05 one sample t-test compared with the 
hypothetical value of 100. 
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4.3.6 Conclusion 
Through comparison of the levels of A1R and A2AR in PC TE and NT, it was 
found that both receptors are enriched in PC nerve terminals. 
The synaptic changes present in PC of suicide completers were then studied, 
and it was observed a down-regulation of PSD-95 density levels with suicide. 
A down-regulation of A1R density in NT, as well as a increase in 
immunoreactivity levels of A2AR in TE, was observed in suicide completers when 
compared with age-matched controls. 
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4.4 Hippocampus 
 
4.4.1 Nerve terminals validation 
To validate hippocampus NT preparation, the relative amount of synaptic and 
glial markers was compared in TE and in NT of the same sample, by Western blot 
analysis, as for the other brain regions. 
We observed an increase in the density of SNAP-25 (42.3% ± 7.3%, n=10), 
synaptophysin (63.5% ± 10.7%, n=9) and PSD-95 (94.5% ± 3.8%, n=6) in NT 
preparation compared to TE (Figure 28). 
We also observed a decrease in the density of GFAP in NT (30.1% ± 6.5%, 
n=12) than in TE (Figure 28). 
These results indicate that the synaptic markers SNAP-25, synaptophysin and 
PSD-95 are enriched in hippocampus nerve terminals as compared with total extracts, 
and as expected there is an enrichment of GFAP density in total extracts when 
compared with the nerve terminals preparation. Thus validating human nerve terminals 
isolation in hippocampus. 
 
 
Figure 28. Validation of NT preparations from hippocampus - using several synaptic 
markers (SNAP-25, synaptophysin and PSD-95) and a glial marker (GFAP). The data 
is presented in percentage of total extracts. Data are mean±SEM of n=6-12, * p<0.05, 
one sample t-test compared with the hypothetical value of 100. 
 
 
 
 
Role of adenosine receptors in suicide 
60 
 
4.4.2 Adenosine receptors localization 
To comprehend the normal localization of A1R, we used Western blot analysis, 
to compare the relative abundance of A1R in TE and in NT of hippocampus of the same 
sample. 
We observed an increase in the immunoreactivity of A1R (62.2% ± 13.6%, n=6) 
in NT preparation compared to TE (Figure 29). 
 
 
Figure 29. A1R enrichment in nerve terminals from hippocampus. (A) A1R are enriched 
in nerve terminals. (B) Representative Western blot of the A1R levels in both 
preparations. (C) Representative Western blot of the β-actin density (control for protein 
loading). The data is presented in percentage of total extracts. Data are mean±SEM of 
n=6. * p<0.05, one sample t-test compared with the hypothetical value of 100. 
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4.4.3 Adenosine receptors subsynaptic localization 
After observing that there is an enrichment of A1R in hippocampus NT, we went 
to refine the information on its subsynaptic localization. It was analyzed how A1R is 
distributed in the different subsynaptic fractions, using a fractionation procedure 
(Phillips et al., 2001), previously validated by our group (Rebola et al., 2005). 
 
4.4.3.1 A1 receptor 
The data presented in Figure 30 shows that A1R is located in all fractions of 
synaptosomes.  
 
 
Figure 30. A1R is present is in all synaptic fractions of hippocampus. (A) MC 
subsynaptic levels of A1R. (B) Representative Western blot of the subsynaptic 
distribution of A1R. (C) The efficiency of the fractionation is illustrated by the ability to 
recover the immunoreactivity for SNAP-25 in the presynaptic active zone (PRE), PSD-
95 in the postsynaptic density (POST) and synaptophysin in the extrasynaptic fraction 
(EXTRA). The data are present as mean±SEM of n=4, one-way ANOVA. 
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4.4.4 Synaptic markers in suicide 
Then we went to determine the changes of synaptic markers in hippocampus 
NT, namely SNAP-25, synaptophysin and PSD-95, with suicide. This was assessed by 
Western blot analysis, and the immunoreactivity of each band was normalized with β-
actin. 
In hippocampus NT, no significant differences were found, in the 
immunoreactivity of SNAP-25 (162.4% ± 41.3%, n=7) and synaptophysin (114.7% ± 
14.5%, n=5), in the suicide group compared with non-suicide controls (Figure 31). 
There was a decrease in PSD-95 density (29.3% ± 8.0%, n=4) with suicide 
(Figure 31). 
 
 
Figure 31. Down-regulation of PSD-95 density with suicide in nerve terminals from 
hippocampus. (A) PSD-95 density decreases with suicide in nerve terminals. (B) 
Representative Western blot of the PSD-95 levels in the suicide and control samples. 
(C) Representative Western blot of the β-actin density (control for protein loading). The 
data is presented in percentage of control nerve terminals. Data are mean±SEM of 
n=4-7. * p<0.05, one sample t-test compared with the hypothetical value of 100. 
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4.4.5 Astrocytes in suicide 
 
Additionally, we also tested for an astrocytic marker to gauge for changes of 
astrocytes in the hippocampus of suicide completers. This was assessed by Western 
blot analysis, and the immunoreactivity of each band was normalized with β-actin. 
In hippocampus, the GFAP density decreased (17.5% ± 4.1%, n=6), in TE with 
suicide (Figure 32). 
 
 
Figure 32. Down-regulation of GFAP density with suicide in total extracts from 
hippocampus. (A) GFAP density decreases with suicide in nerve terminals. (B) 
Representative Western blot of GFAP levels in the suicide and control samples. (C) 
Representative Western blot of the β-actin density (control for protein loading). The 
data is presented in percentage of control total extracts. Data are mean±SEM of n=6. * 
p<0.05, one sample t-test compared with the hypothetical value of 100. 
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4.4.6 Conclusion 
In conclusion, by comparing the levels of A1R in hippocampus TE and NT, it 
was found that, such as in all the other areas previously studied, A1R are enriched in 
NT, and that they are present in all synaptic fractions. 
We also showed a down-regulation of PSD-95 and GFAP density levels with 
suicide, providing information on synaptic and astrocytic changes present in 
hippocampus of suicide completers. 
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4.5 [14C]Glutamate release from synaptosomes 
 
We aimed to define if there is an deregulation of the function of synaptic ARs in 
individuals who committed suicide; for this purpose, we merged our expertise in 
following the chemically-evoked release of neurotransmitters such as glutamate from 
human NT (Katona et al., 2000) with our pharmacological expertise to characterize 
A2AR controlling glutamate release from rodents (Lopes et al., 2002) to compare the 
impact of A1R and A2AR on the evoked glutamate release from human P2 crude 
synaptosomes from amygdala, BA25, MC, and hippocampus of controls, with a PMI of 
less than 24 h. 
The evoked release of [14C]glutamate from chemically-stimulated P2 crude 
synaptosomes, was carefully optimized in human tissue from the different brain areas. 
These preliminary results confirmed that this protocol can be used for studying 
the neurotransmitters release from synaptosomes using human postmortem samples, 
which will allow further studies, to comprehend the changes in ARs modulatory function 
with suicide. 
 
 
Figure 33. [14C]Glutamate release from synaptosomes. (A) BA25. (B) MC. (C) 
Hippocampus. 
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5.1 Adenosine receptors localization 
 
Purines and purine nucleotides are essential to all living cells (Arch & 
Newsholme, 1978; van den Berghe et al., 1992), being released not only from neurons 
but also from other cells producing several effects on multiple organ systems by 
binding to purinergic receptors, widespread in the brain (Stone et al., 2009). Adenosine 
is an important molecule in brain signalling, controling the flow of information so that 
synaptic transmission can occur in a harmonic way. Extracelular acummulation of 
adenosine is connected with neurotransmitters release and to neuronal firing frequency 
and intensity (Cunha, 2005; Dunwiddie & Haas et al,. 1985). 
The knowledge about adenosine receptors (ARs) localization in the human 
brain, both celular and synaptic, provides an important insight on the adenosine 
modulatory role. 
From our results, we can assume that both adenosine A1 receptor (A1R) and 
adenosine A2A receptor (A2AR) display a predominant synaptic localization, being also 
present, at substantially lower levels, in other neuronal locations and cell types. 
 
Previous PET studies in human volunteers, and autoradiographic studies in 
postmortem human brain samples, have investigated the distribution of A1R, using 
radioligands. A1R wide distribution in the human brain was denoted and it was shown 
that they are not homogeneously located in all cortex regions, with strong labelling in 
pyramidal cells (Fukumitsu et al., 2005; Schindler et al., 2001). 
Our results, on A1R localization, are in agreement with previous studies, in 
which they were also found in all synaptic fractions (Fredholm et al., 2005; Schubert et 
al., 1994). So we can infer, from research done in rodents, an adenosine role in 
inhibiting neuronal excitability and synaptic transmission mediated through the 
activation of synaptic A1R (Fredholm et al., 2005; Greene & Haas, 1991; Phillis & Wu, 
1981; Ribeiro et al., 2002; Schubert et al., 1994).  
Presynaptic A1R, in animal models, inhibit synaptic transmission, this may rely 
on the coupling of A1R to the inhibition of N-type calcium channels (Lopes et al., 2011; 
Wu & Saggau, 1994; Yawo & Chuhma, 1993) leading to a decreased stimulus-evoked 
release of glutamate (Proctor & Dunwiddie, 1987; Thompson et al., 1992; Dunwiddie & 
Haas, 1985; Ambrósio et al., 1997). They can also decrease miniature events in 
excitatory synapses, probably depending on presynaptic A1R ability to down-regulate 
the sensitivity of the release apparatus (Rebola et al, 2003, 2005).  
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From studies performed in rodents, A1R located in the postsynaptic density 
manage signal integration and can impact the responsiveness to excitatory stimuli 
controlling simultaneously N-type calcium channels and N-methyl-D-aspartate (NMDA) 
receptors, to survey neuronal firing burst, by leading to neuronal hyperpolarization (de 
Mendonça et al., 1995; de Mendonça & Ribeiro, 1997; Klishin et al., 1995). 
Extrasynaptic A1R may also be important to control potassium currents, 
inducing neuronal hyperpolarization, as it happened in animals (Greene & Haas, 1991). 
As previously stated, although less abundant, A1R also have non-neuronal 
localizations, which we know from rodents, it is important to modulate both astrocytic 
and microglia function in brain (van Calker & Biber, 2005). 
 
A2AR display a widespread distribution in the brain (Fredholm et al., 2005) more 
abundantly in several basal ganglia structures (Svenningsson et al., 1997), where they 
control psychomotor behavior (Xu, 2005). Accordingly with our results, they are mostly 
located in synapses. A2AR play an essential role in synaptic plasticity control, rather 
than having an impact on the control of basal synaptic transmission (d’Alcantara et al., 
2001; Rebola et al., 2008). 
From studying their synaptic localization we observed that A2AR are mainly 
located outside the active zone, although they are also present in the presynaptic 
active zone and postsynaptic density, at a considerably lower level. 
Their extrasynaptic location may have an important role to control extrasynaptic 
glutamate levels, extrapolating from studies in animals, A2AR might control glutamate 
excitotoxicity and the consequent trigger of neuronal dysfunction of brain circuits. In 
primates striatopallidal complex, metabotropic glutamate receptors (mGluR) showed a 
localization similar to that described for A2AR in rats (Hettinger et al., 2001), being 
commonly found postsynaptically and perisynaptically to asymmetric synapses (Smith 
et al., 2000). Previous studies have reported functional evidence for the possible 
existence of synergistic A2AR/mGluR5 interactions modulating the function of the 
GABAergic striatopallidal neurons (Díaz-Cabiale et al., 2002), in rat striatum and in 
membrane preparations from human embryonic kidney (HEK)-293 cells transiently 
cotransfected with both receptors. These results suggest that A2AR may have 
synergistic interactions implicated in neuronal function and dysfunction (Ferré et al., 
2002). 
Accordingly to studies performed in rodents, in the pre-synaptic active zone, 
they can control the release of glutamate and the shutting down of the A1R-mediated 
inhibition of synaptic transmission (Lopes et al., 1999, Rebola et al., 2005), which 
enhances synaptic efficiency upon increasing neuronal activity. A2AR appear to be 
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recruited upon high frequency stimulation triggering synaptic plasticity (Rebola et al., 
2008). 
Postsynaptic A2AR, can control NMDA receptors (Rebola et al., 2008; Wirkner et 
al., 2004), modulating AMPA mediated currents (Dias et al., 2012), as seen in studies 
performed on rodents. 
Although, their neuronal function, ARs are also located in other cell types in the 
brain, such as glial cells. So their activation should not be restricted to direct neuronal 
activity control, participating also in neuron-glia communication (Cunha, 2005; 
Fernandez et al., 1996; Pinto-Duarte et al., 2005). For instance, extrapolating from 
results in animals, astrocytic A2AR could control synaptic plasticity and 
neurodegeneration, by sensing synaptic transmission to adjust glutamate extracellular 
levels; through modulation of transporters activity (Matos et al., 2012); or exocytotic 
glutamate release (Li et al., 2001; Nishizaki et al., 2002). 
 
So, there are different populations of ARs located in different cellular and sub-
cellular populations that may play different roles in the control of neuronal circuits 
function.  
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5.2 Alterations in suicide 
 
Synaptic dysfunction is a key aspect of depression (Duman & Aghajanian, 
2012). Furthermore ARs, as previously demonstrated in animal models (Rebola et al., 
2005), and now in human samples, are mainly synaptic receptors. Besides, we know 
that A2AR have an impact on cognitive dysfunction only in conditions involving synaptic 
deterioration, by way of controlling neurodegeneration (Cunha G et al., 2008). So, it is 
possible that mood-related disorders trigger a synaptic dysfunction, accompanied by a 
deregulation of ARs. The performed evaluation of the loss of synaptic markers in 
suicide completers may then be extremely helpful in identifying the molecular 
mechanisms underlying the mood-associated impairments. 
From our observations, we have denoted an altered density of synaptosomal-
associated protein 25 (SNAP-25) with down-regulation in both, nerve terminals of 
cingulate cortex (BA25) and medial caudate nucleus (MC) of suicide completers. This 
may be in accordance with previous research, showing decreased volume of caudate 
nucleus and altered connectivity with cingulate cortex (Bluhm et al., 2009; Pizzagalli et 
al., 2009). In previous observations, in human frontal cortex, no changes, in SNAP-25 
levels relative to controls, were observed in depressed suicide patients (Honer et al., 
2002). 
Altered expression of SNARE proteins, particullarly SNAP-25, can contribute to 
impaired synaptic neurotransmission (Owe-Larsson et al., 1999) and abnormal 
behavior, leading to suicidal behavior such as disinhibition, impulsivity and 
aggressiveness (Mann, 1998). These alterations may be involved in difficulty on 
initiating behavior and motor movements, as well as in learning, memory, pleasure, 
motivation and social behavior disability. So, impaired reward-processing due to, basal 
ganglia and cortical, dysfunctional cognitive and motor regulation, may also be 
responsible for the anhedonic symptoms of MDD (Bluhm et al., 2009; Butters et al., 
2009; Parashos et al., 1998). For instance, animals with reduction in SNAP-25 display 
behavioral and neurochemical abnormalities (Hess et al., 1992, 1996; Heyser et al., 
1995), reduced glutamate content and impaired release mechanisms (Raber et al., 
1997).  
At synaptic sites, postsynaptic density protein 95 (PSD-95) plays a key role in 
mediating trafficking, clustering, and downstream signaling events, following receptor 
activation (Feyissaa et al., 2009). We have observed a loss of PSD-95 in the posterior 
caudate nucleus and hippocampus of suicide completers. This observation is in 
accordance to what was demonstrated in the literature, patients with depressive 
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disorders exhibit characteristics of synaptic dysfunction in hippocampus (Jorgensen & 
Riederer, 1985), and a study examining the expression of PSD-95 shows a decrease in 
protein expression levels in depressed subjects relative to controls, in prefrontal cortex 
(PFC) (Feyissaa et al., 2009). That is in accordance with previous studies, performed in 
animal models, in which it was observed an impaired synaptic plasticity, a modified 
pattern of glutamate release and a loss of synaptic markers. This is consistent with the 
memory impairments associated with depression (Batalha et al., 2013; Cunha et al., 
2006; Cunha & Agostinho, 2010), and may also be involved in anhedonia. 
 
Several structural and cellular changes, including marked glial anomalies, have 
been observed in association with MDD (Sanacora & Banasr, 2013). Our results have 
shown a decreased level of the glial fibrillary acidic protein (GFAP) in both BA25 and 
hippocampus. This protein, although expressed by several cell types in the CNS, is 
considered an astrocytic marker (Sanacora & Banasr, 2013). Previous postmortem 
reports of mood disorder patients have shown evidences for glial cell pathology, in the 
PFC, ACC, amygdala, and hippocampus (Sanacora & Banasr, 2013). Notably, GFAP 
expression has been reported to decrease in frontal cortex of individuals with 
psychiatric conditions, such as schizophrenia, bipolar disorder and depression 
(Johnston-Wilson et al., 2000). 
Astrocytes communicate bidirectional with neurons at the synaptic level by 
responding to synaptic activity in order to modulate synaptic transmission (Haydon, 
2001; Volterra & Meldolesi, 2005). Besides releasing glutamate, purines (ATP and 
adenosine), GABA, and D-serine (Halassa et al., 2007; Haydon, 2001; Perea et al., 
2009) they can also influence synaptic function through the release of growth factors 
and related molecules (Barres, 2008). 
As already explained, astrocytic pathology may impact brain function at the 
levels of synapses, circuits and behavior (Fiacco et al., 2009), and glia, especially 
astrocytes, can regulate the levels of extracellular glutamate, and thus protecting 
neurons from cell death and provide them energy. So, astrocytic deregulation may 
promote glutamate-mediated neuronal excitotoxicity and lead to altered synaptic 
transmission (Stockmeier & Rajkowska, 2004), already associated with many other 
brain disorders (Sheldon and Robinson, 2007; Kim et al., 2011).  
Altered sleep homeostasis is one of MDD symptoms and, as previously 
mentioned, a night of total SD is one of instant relief therapies used for suicidal patients 
(Germain et al., 2008; Hemmeter et al., 1998). Adenosine-astrocytic signaling is 
implicated in the control of human sleep and gliotransmission seems to be altered in 
areas that contribute to depressive symptoms, such as frontal cortex and hippocampus 
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(Bachmann et al., 2012; Mazzotti et al., 2011). SD, in mice, elevates astrocyte-derived 
adenosine, and the elevation of extracelular adenosine levels activates A1 synaptic 
receptors signaling, which promotes the antidepressants effects (Hines et al., 2013). 
So, the decrease of astrocytes, in these brain regions, can also contribute to a 
reduction: in the astrocytic release of adenosine and in the consequent A1 synaptic 
receptors activation and signaling, leading to disturbed sleep, a known depressive 
symptom. 
 
From our results, posterior caudate nucleus A1 synaptic receptors levels are 
decreased, which is accompained by a down-regulation of PSD-95, a post-synaptic 
density marker of excitatory nerve terminals. So, it is possible that there could be a loss 
of synaptic density in suicide (Feyissaa et al., 2009), these synaptic alterations may be 
associated with the loss of A1R present in the synapse. 
This A1R down-regulation role in depression is supported by the observations of 
anxiolytic actions of A1R agonists administration in rodents (Florio et al., 1998; Jain et 
al., 1995). A loss of the synaptic A1R, important in management of signal integration 
and neuronal hyperpolarization (de Mendonça et al., 1995; de Mendonça & Ribeiro, 
1997; Klishin et al., 1995; Thompson et al., 1992), can be responsible for a decrease in 
adenosine signaling. This can explain some depressive symptoms related to the 
emotional-motor circuitry, such as anhedonia and psychomotor dysfunctions (Furman 
et al., 2011). 
So, in cases such as depression, in which the cell is overstimulated, the A1R 
activation leads to an inhibition of the cell activity. The observed up-regulation of A1R in 
the caudate nucleus is probably a system attempt to control the overstimulation. 
In noxious brain conditions, extracellular adenosine levels increase and ARs are 
activated. If this overexpression is prolonged ARs levels will suffer modifications, A2AR 
will be activated and A1R desensitized, that will contribute to hamper the 
neuroprotective effectiveness of the A1R activation in chronic brain pathologies 
(Fredholm, 1997; Fernandez et al., 1996). Accordingly, A2AR levels are usually 
increased, whereas those of A1R are decreased, in hippocampus (Cunha, 2005). Also 
in older animals, presenting an ARs imbalance (Canas et al., 2009; Cunha et al., 
1995), altered transduction mechanisms associated to ARs were described (Lopes et 
al., 1999), suggesting that A1R and A2AR balance is essential to adenosine role, as a 
normalizing device to promote the adequate response in neuronal circuits. 
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A2AR, in total extracts from BA25 and posterior caudate nucleus, underwent an 
up-regulation with suicide, which can be associated with a gain of function, as A2AR 
overactivation may facilitate excitatory neurotransmission to the caudate nucleus. 
This may be related with the already reported synaptic and astrocytic 
dysfunction that underlies both memory impairment and mood-related alterations. 
This rationale is in agreement with studies performed on both animal models of 
memory dysfunction and of mood alterations showing synaptic changes (Honer et al., 
2002). Besides, blockade of A2AR has previously been reported to decrease cortical 
damage (Gao & Phillis, 1994; Chen et al., 1999; Melani et al., 2003; Behan & Stone, 
2002). The evidence of deregulation of A2AR expression is in line with studies showing 
that A2AR have a central role in anxiety-related disorders under many different 
conditions (Shen & Chen, 2009). Also, A2AR null mice are a valuable model to study 
mood disorders (Deckert, 1998), as these mice display absence of an anxiogenic 
response (El Yacoubi et al., 2000; Ledent et al., 1997).  
Additionally, A2AR are enriched in the caudate-putamen and nucleus 
accumbens, where they can interact physically with dopamine D2R to regulate reward, 
habitual behavior and locomotor activity (Cunha et al., 2008). it has previous been 
reported, in pathological situations (Agostinho et al., 2000; Rebola et al., 2003) and 
upon chronic stress, directed to the basal ganglia (Pinna et al., 2002; Tomiyama et al., 
2004), an increase in A2AR expression levels. Besides, activation of A2AR, whose levels 
where found increased on noxious stimulli (Kobayashi & Millhorn, 1999; Kobayashi et 
al., 2000), leads to enhanced glutamate extracelular levels (Marcoli et al., 2003; Melani 
et al., 2003; Popoli et al., 2002; O’Reagan et al., 1992). 
The fact that their levels were only altered in total extracts, but not in nerve 
terminals, pointed that A2AR expressed in non-neuronal cells may be affected by this 
disorder. As A2AR are expressed in neurons, astrocytes and microglia, they have been 
implicated in controlling glial function and brain metabolic adaptation, processes that 
are deregulated in several psychiatric conditions (Lee et al., 2007; Rajkowska & 
Miguel-Hidalgo, 2007). Thus A2AR up-regulation may be explained by their non-
neuronal role in controlling aberrant synaptic plasticity, once we know that glutamate 
release from astrocytes (Li et al., 2001; Nishiazaki et al., 2002) is enhanced by A2AR in 
rodents. Furthermore, A2AR were found to control glutamate uptake by glial cells 
(Matos et al., 2012), through inhibition of glutamate transport into astrocytes (Pintor et 
al., 2004). 
So, A2AR overactivation, may be a cause or an aggravating factor for disease 
state and may explain why neuroprotection afforded by A2AR blockade is evident in 
cortical (Cunha, 2005) and striatal (Popoli et al., 2002) areas.  
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Chapter 6. Conclusions 
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The results presented in our work provide a comparative analysis of the 
synaptic and subsynaptic distribution of adenosine receptors on cingulated cortex, 
caudate nucleus and hippocampus tissue, in human postmortem samples. 
Besides, we reported MDD pathology-related changes in the distribution of 
synaptic and astrocytic proteins, as well as of the relative abundance alterations of A1R 
and A2AR with suicide. This might explain the relationship of caffeine consumption with 
a decrease incidence of depression and suicide, and thus providing possible molecular 
targets that are responsible for dysfunction in MDD.  
Moreover we carefully optimized the evoked release of [14C]glutamate from 
chemically-stimulated P2 crude synaptosomes protocol in human tissue, and confirmed 
that this protocol can be used for studying the neurotransmitters release from 
synaptosomes using human postmortem samples. 
However, there are some questions that remain unanswered. One of them is if 
A2ARs show the same localization pattern in hippocampus as in other brain regions, 
and if hippocampal ARs suffer changes with suicide. Localization of ARs in glial cells 
and their astrocytic function still remains to be explored. Also, we aim to define if there 
is an deregulation of the modulatory function of ARs in suicide completers. Additionally, 
we look forward to explore these alterations in amygdala. 
Nevertheless, our work might contribute to better understand the modulatory 
role of ARs in depression. This will probably be a setting up point for further research, 
involving the development of more effective and neuroprotective therapeutical 
approaches, able to control the progression of mood-related disorders, particularly 
MDD. 
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